Longeveron (LGVN) 10-K 14 Mar 23 2022 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 07, 2023	Jun. 30, 2022
Document Information Line Items
Entity Registrant Name	LONGEVERON INC.
Trading Symbol	LGVN
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Public Float			$ 18,000,000
Amendment Flag	false
Entity Central Index Key	0001721484
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-40060
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-2174146
Entity Address, Address Line One	1951 NW 7th Avenue
Entity Address, Address Line Two	Suite 520
Entity Address, City or Town	Miami
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33136
City Area Code	(305)
Local Phone Number	909-0840
Title of 12(b) Security	Common Stock, par value $0.001
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Auditor Firm ID	688
Auditor Name	Marcum llp
Auditor Location	Hartford, CT
Class A Common Stock
Document Information Line Items
Entity Common Stock, Shares Outstanding		6,163,050
Class B Common Stock
Document Information Line Items
Entity Common Stock, Shares Outstanding		14,871,085

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 10,503	$ 25,658
Marketable securities	9,155	9,385
Prepaid expenses and other current assets	404	282
Accounts and grants receivable	218	55
Total current assets	20,280	35,380
Property and equipment, net	2,949	3,062
Intangible assets, net	2,409	2,334
Right-of-use (ROU) asset	1,531	1,813
Other assets	244	177
Total assets	27,413	42,766
Current liabilities:
Accounts payable	1,751	645
Accrued expenses	650	1,327
Current portion of lease liability	564	537
Estimated lawsuit liability	1,398
Deferred revenue	506	199
Total current liabilities	4,869	2,708
Lease liability	2,041	2,605
Total long-term liabilities	2,041	2,605
Total liabilities	6,910	5,313
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.001 par value per share, 5,000,000 shares authorized, no shares issued and outstanding at December 31, 2022 and 2021
Class A Common Stock, $0.001 par value per share, 84,295,000 shares authorized, 6,127,320 shares issued and outstanding at December 31, 2022; 5,175,361 shares issued and outstanding at December 31, 2021	6	5
Class B Common Stock, $0.001 par value per share, 15,705,000 shares authorized, 14,891,085 shares issued and outstanding at December 31, 2022; 15,702,834 shares issued and outstanding at December 31, 2021	15	16
Additional paid-in capital	83,712	81,470
Stock subscription receivable	(100)	(100)
Accumulated deficit	(62,773)	(43,938)
Accumulated other comprehensive loss	(357)
Total stockholders’ equity	20,503	37,453
Total liabilities and stockholders’ equity	$ 27,413	$ 42,766

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Class A Common Stock
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	84,295,000	84,295,000
Common stock, shares issued	6,127,320	5,175,361
Common stock, shares outstanding	6,127,320	5,175,361
Class B Common Stock
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	15,705,000	15,705,000
Common stock, shares issued	14,891,085	15,702,834
Common stock, shares outstanding	14,891,085	15,702,834

Statements of Operations

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenues
Grant revenue	$ 282	$ 598
Clinical trial revenue	940	708
Total revenues	1,222	1,306
Cost of revenues	725	716
Gross profit	497	590
Operating expenses
General and administrative	8,119	9,740
Research and development	9,370	7,092
Selling and marketing	1,051	1,214
Total operating expenses	18,540	18,046
Loss from operations	(18,043)	(17,456)
Other (expenses) and income
Lawsuit expense	(1,398)
Forgiveness of Paycheck Protection Program loan		300
Interest expense		(4)
Other refundable tax credits	306	58
Other income, net	300	57
Total other (expenses) and income, net	(792)	411
Net loss	$ (18,835)	$ (17,045)
Basic and diluted net loss per share (in Dollars per share)	$ (0.9)	$ (0.9)
Basic and diluted weighted average common shares outstanding (in Shares)	20,969,032	18,915,086

Statements of Operations (Paren

Statements of Operations (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Diluted net loss per share	$ (0.90)	$ (0.90)
Diluted weighted average common shares outstanding	20,969,032	18,915,086

Statements of Comprehensive Los

Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (18,835)	$ (17,045)
Other comprehensive loss:
Net unrealized losses on available-for-sale securities	(357)
Total comprehensive loss	$ (18,478)	$ (17,045)

Statements of Stockholders_ Equ

Statements of Stockholders’ Equity - USD ($) $ in Thousands	Class A Common Stock	Class B Common Stock	Member Units Number of Units	Subscription Receivable	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Balance at Dec. 31, 2020			$ 2,057	$ (100)				$ 1,957
Balance (in Shares) at Dec. 31, 2020			2,062,764
Conversion of Units into Class A and B common stock		$ 16	$ (2,057)		28,934	(26,893)
Conversion of Units into Class A and B common stock (in Shares)	338,030	15,702,834	(2,062,764)
Initial public offering and overallotment of Class A Common Stock, net of $2,969 in issuance costs	$ 3				26,131			26,134
Initial public offering and overallotment of Class A Common Stock, net of $2,969 in issuance costs (in Shares)	2,910,000
PIPE offering of Class A Common Stock, net of $1,968	$ 1				18,494			18,495
PIPE offering of Class A Common Stock, net of $1,968 (in Shares)	1,169,288
Class A Common Stock, issued for RSUs vested	$ 1							1
Class A Common Stock, issued for RSUs vested (in Shares)	657,066
Class A Common Stock, held for taxes on RSUs vested					(452)			(452)
Class A Common Stock, held for taxes on RSUs vested (in Shares)	(123,662)
Class A Common Stock, issued for warrant exercises					613			613
Class A Common Stock, issued for warrant exercises (in Shares)	51,061
Class A Common Stock, issued for stock option exercises					10			10
Class A Common Stock, issued for stock option exercises (in Shares)	1,812
Class A Common Stock, issued for consulting					1,297			1,297
Class A Common Stock, issued for consulting (in Shares)	171,766
Equity-based compensation					6,443			6,443
Net loss						(17,045)		(17,045)
Balance at Dec. 31, 2021	$ 5	$ 16		(100)	81,470	(43,938)		37,453
Balance (in Shares) at Dec. 31, 2021	5,175,361	15,702,834
Conversion of Class B common stock for Class A common stock	$ 1	$ (1)
Conversion of Class B common stock for Class A common stock (in Shares)	811,749	(811,749)
Class A Common Stock, issued for RSUs vested
Class A Common Stock, issued for RSUs vested (in Shares)	172,274
Class A Common Stock, held for taxes on RSUs vested					(304)			(304)
Class A Common Stock, held for taxes on RSUs vested (in Shares)	(32,438)
Class A Common Stock, issued for stock option exercises					2			2
Class A Common Stock, issued for stock option exercises (in Shares)	374
Class A Common Stock, issued for consulting					207			207
Equity-based compensation					2,337			2,337
Unrealized loss attributable to change in market value of available for sale investments							(357)	(357)
Net loss						(18,835)		(18,835)
Balance at Dec. 31, 2022	$ 6	$ 15		$ (100)	$ 83,712	$ (62,773)	$ (357)	$ 20,503
Balance (in Shares) at Dec. 31, 2022	6,127,320	14,891,085

Statements of Stockholders_ E_2

Statements of Stockholders’ Equity (Parentheticals) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Statement of Stockholders' Equity [Abstract]
Net of issuance costs	$ 2,969
Sale of net price	$ 1,968

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net loss	$ (18,835)	$ (17,045)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	893	914
Forgiveness of Paycheck Protection Program loan		(300)
Loss on sale of equipment		60
Change in fair value of marketable securities		85
Equity issued to employees and consultants	170	1,297
Equity-based compensation	2,167	6,443
Non-operating lawsuit expense	1,398
Changes in operating assets and liabilities:
Accounts and grants receivable	(164)	366
Prepaid expenses and other current assets	(122)	(227)
Other assets	(15)	(4)
Accounts payable	1,106	(945)
Deferred revenue	307	188
Accrued expenses	(677)	(214)
ROU asset and lease liability	(197)	(254)
Net cash used in operating activities	(13,969)	(9,636)
Cash flows from investing activities
Marketable securities	179	(9,471)
Acquisition of intangible assets	(287)	(980)
Acquisition of property and equipment	(569)	(330)
Proceeds from sale of equipment		85
Net cash used in investing activities	(677)	(10,696)
Cash flows from financing activities
Proceeds from initial public offering of common stock, net of commissions and expenses		26,695
Proceeds from secondary offering		18,495
Proceeds from warrants exercised		613
Proceeds from stock options exercised	2	10
Repayments of short-term note payable		(38)
Repayments of EIDL loan		(150)
Payments for Consulting fees with RSUs	(207)
Payments for taxes on RSUs vested	(304)	(451)
Net cash (used) provided by financing activities	(509)	45,174
(Decrease) Increase in cash and cash equivalents	(15,155)	24,842
Cash and cash equivalents at beginning of the period	25,658	816
Cash and cash equivalents at end of the period	10,503	25,658
Supplement Disclosure of Non-cash Investing and Financing Activities:
Conversion of Series A, B and C units into Class A and B common stock		(2,057)
Vesting of RSUs into Class A Common Stock		(2,398)
Increase in deferred offering costs included in accounts payable and accrued expenses		$ 171

Nature of Business, Basis of Pr

Nature of Business, Basis of Presentation, and Liquidity	12 Months Ended
	Dec. 31, 2022
Nature of Business, Basis of Presentation, and Liquidity [Abstract]
Nature of Business, Basis of Presentation, and Liquidity	1. Nature of Business, Basis of Presentation, and Liquidity Nature of business: On February 12, 2021, Longeveron LLC converted its corporate form (the “Corporate Conversion”) from a Delaware limited liability company (Longeveron, LLC) to a Delaware corporation, Longeveron Inc. (the “Company,” “Registrant,” “Longeveron” or “we,” “us,” or “our”). Longeveron LLC was formed as a Delaware limited liability company on October 9, 2014 and authorized to transact business in Florida on December 15, 2014. The Company is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company operates out of its leased facilities in Miami, Florida. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on licenses, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive pre-clinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting capabilities. The Company’s product candidates are currently in development. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from, among others, existing pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, partners and consultants. Initial Public Offering (“IPO”): On February 12, 2021 our Class A Common Stock, par value $0.001 per share (the “Class A Common Stock”) began to trade on NASDAQ under the stock symbol “LGVN”. Pursuant to the IPO, the Company sold 2,660,000 shares of Class A Common Stock at a public offering price of $10.00 per share for aggregate gross proceeds of $26.6 million prior to deducting underwriting discounts, commissions, and other offering expenses. In addition, the Company granted the underwriters a 30-day option to purchase up to an additional 399,000 shares at the public offering price less the underwriting discounts and commissions. On March 15, 2021, the Company’s underwriters partially exercised the over-allotment option, resulting in the Company selling an additional 250,000 shares of Class A Common Stock at a public offering price of $10.00 per share for aggregate gross proceeds of $2.5 million prior to deducting underwriting discounts, commissions, and other offering expenses. Private Placement On December 3, 2021, the Company completed a private placement with several investors, wherein a total of 1,169,288 shares of the Company’s Class A Common Stock were issued at a purchase price of $17.50 per share, with each investor also receiving a warrant to purchase up to a number of shares of Class A Common Stock equal to the number of shares of Class A Common Stock purchased by such investor in the Offering, at an exercise price of $17.50 per share (the “Purchaser Warrants”), for a total purchase price of approximately $20.5 million (the “2021 PIPE Offering”). The Purchaser Warrants are immediately exercisable, expire five years from the date of issuance and have certain downward pricing adjustment mechanisms, subject to a floor, as set forth in greater detail therein. In addition, the Company granted the underwriters warrants, under similar terms, to purchase 46,722 shares of Class A Common Stock at an exercise price of $17.50 per share. Basis of presentation: The financial statements of the Company were prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”). Certain reclassifications have been made to prior period amounts to conform to the current period presentation. These reclassifications had no impact on previously reported net loss for the year ended December 31, 2022. Liquidity: Since inception, the Company has primarily been engaged in organizational activities, including raising capital, and research and development activities. The Company does not yet have a product that has been approved by the U.S. Food and Drug Administration (“FDA”), and has only generated revenues from grants, the Bahamas Registry Trial and contract manufacturing. The Company has not yet achieved profitable operations or generated positive cash flows from operations. The Company intends to continue its efforts to raise additional equity financing, develop its intellectual property, and secure regulatory approvals to commercialize its products. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. Further, the Company’s future operations are dependent on the success of the Company’s efforts to raise additional capital, its research and commercialization efforts, regulatory approval, and, ultimately, the market acceptance of the Company’s products. These financial statements do not include adjustments that might result from the outcome of these uncertainties. The Company has incurred recurring losses from operations since its inception, including a net loss of $18.8 million and $17.0 million for the years ended December 31, 2022 and 2021, respectively. In addition, as of December 31, 2022, the Company had an accumulated deficit of $62.8 million. The Company expects to continue to generate operating losses for the foreseeable future. As of December 31, 2022, the Company had cash, and cash equivalents of $10.5 million and marketable securities of $9.2 million. The Company believes that its cash and cash equivalents and investments as of December 31, 2022 will enable it to fund its operating expenses and capital expenditure requirements through at least the next 12 months from the date of issuance of these financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Use of estimates: The presentation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Accounting Standard Updates In December 2019, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2019-12, “Income Taxes (Topic 740)”. The amendments in this ASU simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and by clarifying and amending other areas of Topic 740. The amendments in this ASU are effective for annual and interim periods beginning after December 15, 2020. We adopted this ASU on January 1, 2021 with no material impact on our financial statements. A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any, that the implementation of such proposed standards would have on the Company’s financial statements. Cash and cash equivalents: The Company considers cash to consist of cash and cash equivalents and temporary investments having an original maturity of 90 days or less that are readily convertible into cash. Marketable Securities: Marketable securities at December 31, 2022 and 2021 consisted of marketable fixed income securities, primarily corporate bonds, as well as U.S. Government and agency obligations which are categorized as trading securities and are thus marked to market and stated at fair value in accordance with ASC 820 Fair Value Measurement Investments in Debt and Equity Securities Inventory: The Company will begin carrying inventory of its biological products on its balance sheets following commercial launch of such products. Inventory will consist of raw materials, biological products in process, and finished goods available for sale. The Company will determine its inventory values using the average cost method. Inventory will be valued at the lower of cost or net realizable value and will exclude units that the Company anticipates distributing for clinical evaluation. As of each of December 31, 2022 and 2021, all of the Company’s biological products were anticipated to be distributed for clinical evaluation. The Company does not currently carry any inventory for its biological products, as it has yet to launch a product for commercial distribution. Historically the Company’s operations have focused on clinical trials and discovery efforts, and accordingly, costs of manufactured clinical doses of biological product candidates were expensed as incurred, consistent with the accounting for all other research and development costs. Once the Company begins commercial distribution, costs of all newly manufactured biological products will be allocated either for use in commercial distribution, which will be carried as inventory and not expensed, or for research and development efforts, which will continue to be expensed as incurred. Accounts and grants receivable: Accounts and grants receivable include amounts due from customers, granting institutions and others. The amounts as of December 31, 2022 and 2021 are deemed to be collectible and no amount has been recognized for doubtful accounts. MSCRF-TEDCO (defined below under Revenue Recognition) generally advance grant funds and therefore a receivable is not usually recognized. In addition, for the Clinical trial revenue, most participants pay in advance of treatment. Advanced grant funds and prepayments for the Clinical trial revenue are recorded to deferred revenue. Accounts and grants receivable by source, as of (in thousands): December 31, 2022 2021 National Institutes of Health – Grant $ 218 $ 55 Total $ 218 $ 55 Deferred offering costs: The Company recorded certain legal, professional and other third-party fees that were directly associated with in-process equity financings as deferred offering costs until the applicable equity financing was consummated. After consummation of an equity financing, these costs are recorded in stockholders’ equity as a reduction of proceeds generated as a result of the offering. During 2021, offering costs incurred in connection with the 2021 PIPE Offering of approximately $0.2 million were netted against the proceeds from the private placement. Offering costs of $0.6 million have been prepaid as of December 31, 2020 and then netted against the IPO proceeds as of December 31, 2021. Property and equipment: Property and equipment, including improvements that extend useful lives of related assets, are recorded at cost, while maintenance and repairs are charged to operations as incurred. Depreciation is calculated using the straight-line method based on the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the original term of the lease. Depreciation expense is recorded in the research and development line of the Statement of Operations as the assets are primarily related to the Company’s clinical programs. Intangible assets: Intangible assets include payments on license agreements with the Company’s co-founder and chief scientific officer (“CSO”) and the University of Miami (“UM”) (see Note 9) and legal costs incurred related to patents and trademarks. License agreements have been recorded at the value of cash consideration, common stock and membership units transferred to the respective parties when acquired. Payments for license agreements are amortized using the straight-line method over the estimated term of the agreements, which range from 5-20 years. Patents are amortized over their estimated useful life, once issued. The Company considers trademarks to have an indefinite useful life and evaluates them for impairment on an annual basis. Amortization expense is recorded in the research and development line of the Statements of Operations as the assets are primarily related to the Company’s clinical programs. Impairment of Long-Lived Assets: The Company evaluates long-lived assets for impairment, including property and equipment and intangible assets, when events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Upon the occurrence of a triggering event, the asset is reviewed to assess whether the estimated undiscounted cash flows expected from the use of the asset plus the residual value from the ultimate disposal exceeds the carrying value of the asset. If the carrying value exceeds the estimated recoverable amounts, the asset is written down to the estimated fair value. Any resulting impairment loss is reflected on the statements of operations. Upon evaluation, management determined that there was no impairment of long-lived assets as of December 31, 2022 and 2021. Deferred revenue: The unearned portion of advanced grant funds and prepayments for Clinical trial revenue, which will be recognized as revenue when the Company meets the respective performance obligations, has been presented as deferred revenue in the balance sheets. For the years ended December 31, 2022 and 2021, the Company recognized $0.1 million and $0, respectively, of funds that were previously classified as deferred revenue. Due to the MSCRF – TEDCO – grant ARDS program being discontinued, the $0.4 million recorded as deferred revenue will be reversed when the funds are returned to MSCRF – TEDCO. Revenue recognition: The Company recognizes revenue when performance obligations related to respective revenue streams are met. For Grant revenue, the Company considers the performance obligation met when the grant related expenses are incurred, or supplies and materials are received. The Company is paid in tranches pursuant to terms of the related grant agreements, and then applies payments based on regular expense reimbursement submissions to grantors. There are no remaining performance obligations or variable consideration once grant expense reporting to the grantor is complete. For Clinical trial revenue, the Company considers the performance obligation met when the participant has received the treatment. The Company usually receives prepayment for these services or receives payment at the time the treatment is provided, and there are no remaining performance obligations or variable consideration once the participant received the treatment. For Contract manufacturing revenue, the Company considers the performance obligation met when the contractual obligation and / or statement of work has been satisfied. Payment terms may vary depending on specific contract terms. There are no significant judgments affecting the determination of the amount and timing of revenue recognition. Revenue by source (in thousands): Years ended 2022 2021 National Institute of Health - grant $ 164 $ 212 Clinical trial revenue 940 708 Alzheimer’s Association grant - 260 MSCRF – TEDCO 1 118 126 Contract manufacturing revenue - - Total $ 1,222 $ 1,306 1 Maryland Stem Cell Research Fund (MSCRF) - Maryland Technology Development Corporation (TEDCO) The Company records cost of revenues based on expenses directly related to revenue. For Grants, the Company records allocated expenses for Research and development costs to a grant as a cost of revenues. For the Clinical trial revenue directly related expenses for that program are expensed as incurred. These expenses are similar to those described under “Research and development expense” below. Research and development expense: Research and development costs are charged to expense when incurred in accordance with ASC 730. ASC 730 addresses the proper accounting and reporting for research and development costs. It identifies: 1) those activities that should be identified as research and development; 2) the elements of costs that should be identified with research and development activities, and the accounting for these costs; and 3) the financial statement disclosures related to them. Research and development costs include costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, property and equipment depreciation and allocation of various corporate costs. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by the third parties, patient enrollment in clinical trials, administrative costs incurred by the third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as the related services are rendered. Concentrations of credit risk: Financial instruments which potentially subject the Company to credit risk consist principally of cash and cash equivalents, marketable securities and accounts and grants receivable. Cash and cash equivalents are held in U.S. financial institutions. At times, the Company may maintain balances in excess of the federally insured amounts. Income taxes: Prior to its Corporate Conversion, the Company was treated as a partnership for U.S. federal and state income tax purposes. Consequently, the Company passed its earnings and losses through to its members based on the terms of the Company’s Operating Agreement. Accordingly, no provision for income taxes is recorded in the financial statements for periods prior to the conversion. Following the Corporate Conversion, the Company’s tax provision consists of taxes currently payable or receivable, plus any change during the period in deferred tax assets and liabilities. The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In addition, a valuation allowance is established to reduce any deferred tax asset for which it is determined that it is more likely than not that some portion of the deferred tax asset will not be realized. The Company’s tax provision was $0 for the year ended December 31, 2022 and 2021 due to net operating losses. The Company has not recorded any tax benefit for the net operating losses incurred due to the uncertainty of realizing a benefit in the future. The Company recognizes the tax benefits from uncertain tax positions that the Company has taken or expects to take on a tax return. In the unlikely event an uncertain tax position exists in which the Company could incur income taxes, the Company would evaluate whether there is a probability that the uncertain tax position taken would be sustained upon examination by a taxing authority. Reserves for uncertain tax positions would then be recorded if the Company determined it is probable that either a position would not be sustained upon examination or a payment would have to be made to a taxing authority and the amount was reasonably estimable. As of December 31, 2022 and 2021, the Company does not believe it has any uncertain tax positions that would result in the Company having a liability to the taxing authority. It is the Company’s policy to expense any interest and penalties associated with its tax obligations when they are probable and estimable. Equity-based compensation: The Company accounts for equity-based compensation expense by the measurement and recognition of compensation expense for stock-based awards based on estimated fair values on the date of grant. The fair value of the options is estimated at the date of the grant using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the input of highly subjective assumptions, the most significant of which are the expected share price volatility, the expected life of the option award, the risk-free rate of return, and dividends during the expected term. Because the option-pricing model is sensitive to changes in the input assumptions, different determinations of the required inputs may result in different fair value estimates of the options. Neither the Company’s stock options nor its restricted stock units (“RSUs”) trade on an active market. Volatility is a measure of the amount by which a financial variable, such as a stock price, has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Given the Company’s limited historical data, the Company utilizes the average historical volatility of similar publicly traded companies that are in the same industry. The risk-free interest rate is the average U.S. treasury rate (having a term that most closely approximates the expected life of the option) for the period in which the option was granted. The expected life is the period of time that the options granted are expected to remain outstanding. Options granted have a maximum term of ten years. The Company had insufficient historical data to utilize in determining its expected life assumptions and, therefore, uses the simplified method for determining expected life.

Marketable securities

Marketable securities	12 Months Ended
	Dec. 31, 2022
Marketable securities [Abstract]
Marketable securities	3. Marketable securities The following is summary of marketable securities that the Company measures at fair value: Fair Value at December 31, 2022 Level 1 Level 2 Level 3 Total U.S. Treasury obligations 96,981 - - 96,981 U.S. government agencies - 1,250,003 - 1,250,003 Corporate and foreign bonds - 7,807,655 - 7,807,655 Money market funds (1) 607,262 - - 607,262 Accrued income 64,815 - - 64,815 Total marketable securities $ 769,059 $ 9,057,658 $ - $ 9,826,717 Fair Value at December 31, 2021 Level 1 Level 2 Level 3 Total U.S. Treasury obligations 401,290 - - 401,290 U.S. government agencies - 1,424,477 - 1,424,477 Corporate and foreign bonds - 7,507,705 - 7,507,705 Money market funds (1) 576,742 - - 576,742 Accrued income 52,484 - - 52,484 Total marketable securities $ 1,030,516 $ 8,932,182 $ - $ 9,962,698 (1) Money market funds are included in cash and cash equivalents in the balance sheet. As of December 31, 2021 our assessment of the above marketable securities was that these instruments were considered trading securities; however, based upon our current cash needs, we now believe that these should be categorized as available-for-sale securities as of December 31, 2022. As of December 31, 2022 and 2021, the Company reported accrued interest receivable related to marketable securities of $64,815 and $52,484, respectively. These amounts are recorded in other assets on the Balance Sheets and are not included in the carrying value of the marketable securities. As of December 31, 2022, the Company recorded unrealized losses attributable to changes in marketable securities of $357,334. These unrealized losses were recorded on the Balance sheet as accumulated other comprehensive loss.

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and equipment, net	4. Property and equipment, net Major components of property and equipment are as follows (in thousands): Useful Lives December 31, December 31, Leasehold improvements 10 years $ 4,328 $ 4,318 Furniture/Lab equipment 7 years 2,264 1,724 Computer equipment 5 years 46 28 Software/Website 3 years 38 38 Total property and equipment 6,676 6,108 Less accumulated depreciation and amortization 3,727 3,046 Property and equipment, net $ 2,949 $ 3,062 Depreciation and amortization expense amounted to approximately $0.7 for the years ended December 31, 2022 and 2021.

Intangible Assets, Net

Intangible Assets, Net	12 Months Ended
	Dec. 31, 2022
Intangible assets, net [Abstract]
Intangible assets, net	5. Intangible assets, net Major components of intangible assets as of December 31, 2022 are as follows (in thousands): Useful Lives Cost Accumulated Total License agreements 20 years $ 2,043 $ (685 ) $ 1,358 Patent Costs 887 - 887 Trademark costs 164 - 164 Total $ 3,094 $ (685 ) $ 2,409 Major components of intangible assets as of December 31, 2021, are as follows (in thousands): Useful Lives Cost Accumulated Total License agreements 20 years $ 2,043 $ (473 ) $ 1,570 Patent Costs 615 - 615 Trademark costs 149 - 149 Total $ 2,807 $ (473 ) $ 2,334 Amortization expense related to intangible assets amounted to approximately $0.2 million for the years ended December 31, 2022 and 2021. Future amortization expense for intangible assets as of December 31, 2022 is approximately as follows (in thousands): Year Ending December 31, Amount 2023 $ 224 2024 224 2025 224 2026 89 2027 62 Thereafter 535 Total $ 1,358

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Leases	6. Leases The Company records a Right-of-use (ROU) asset and a lease liability related to its operating leases (there are no finance leases). The Company’s corporate office lease expires in March 2027. As of December 31, 2022, the ROU asset and lease liability were approximately $1.5 million and $2.6 million, respectively. As of December 31, 2021, the ROU asset and lease liability were approximately $1.8 million and $3.1 million, respectively. Future minimum payments under the operating leases as of December 31, 2022 are as follows (in thousands): Year Ending December 31, Amount 2023 $ 687 2024 702 2025 719 2026 735 2027 184 Total 3,027 Less: Interest (5% discount rate) 422 Present Value of Lease Liability $ 2,605 During each of the years ended December 31, 2022 and 2021, the Company incurred approximately $1.0 million of total lease costs that are included in the general and administrative expenses in the statements of operations. On July 1, 2020, the Company entered into a sublease agreement for a portion of its leased space for a one-year period ending June 30, 2021, with optional one-year renewal periods, and $10,000 in monthly payments. The sublease was terminated in the second quarter of 2022. For the year ended December 31, 2022, $27,000 was recognized as sublease income, due to the Company receiving $17,000 of equipment and $10,000 of security deposit forfeited. As compared to the year ended December 31, 2021, where $102,500 was recognized as sublease income and is included in other income in the accompanying statements of operations.

Members' Equity and Stockholder

Members' Equity and Stockholders' Equity	12 Months Ended
	Dec. 31, 2022
Members’ Equity and Stockholders’ Equity [Abstract]
Members’ Equity and Stockholders’ Equity	7. Members’ Equity and Stockholders’ Equity IPO The Corporate Conversion undertaken immediately prior to the Company’s IPO caused all existing Series A and B units to convert into Class B Common Stock and all existing Series C units to convert into Class A Common Stock. The purpose of the Corporate Conversion was to reorganize the Company structure so that the entity that offered the Company’s Class A Common Stock to the public was a Delaware corporation rather than a Delaware limited liability company, and so that the Company’s existing investors own the Company’s Class A Common Stock or Class B Common Stock rather than equity interests in a limited liability company. On February 12, 2021 our Class A Common Stock, par value $0.001 per share (the “Class A Common Stock”) began to trade on NASDAQ under the stock symbol “LGVN”. Pursuant to the IPO, the Company sold 2,660,000 shares of Class A Common Stock at a public offering price of $10.00 per share for aggregate gross proceeds of $26.6 million prior to deducting underwriting discounts, commissions, and other offering expenses. In addition, the Company granted the underwriters a 30-day option to purchase up to an additional 399,000 shares at the public offering price less the underwriting discounts and commissions. On March 15, 2021, the Company’s underwriters partially exercised the over-allotment option, resulting in the Company selling an additional 250,000 shares of Class A Common Stock at a public offering price of $10.00 per share for aggregate gross proceeds of $2.5 million prior to deducting underwriting discounts, commissions, and other offering expenses. 2021 PIPE Offering On December 3, 2021, the Company completed the 2021 PIPE Offering wherein a total of 1,169,288 shares of the Company’s Class A Common Stock were issued at a purchase price of $17.50 per share, with each investor also receiving a warrant to purchase up to a number of shares of Class A Common Stock equal to the number of shares of Class A Common Stock purchased by such investor in the 2021 PIPE Offering, at an exercise price of $17.50 per share (the “Purchaser Warrants”), for a total purchase price of approximately $20.5 million (the “Offering”). The Purchaser Warrants are immediately exercisable, expire five years from the date of issuance and have certain downward pricing adjustment mechanisms, subject to a floor, as set forth in greater detail therein. In addition, the Company granted the underwriters warrants, under similar terms, to purchase 46,722 shares of Class A Common Stock at an exercise price of $17.50 per share. Class A Common Stock On November 16, 2022, the Company accounted for but had not issued 48,140 RSUs convertible to unregistered shares of Class A Common Stock, with an aggregate value of $207,000 as payment for accrued expenses under a consulting agreement with Dr. Hare. On October 3, 2022, a total of 20,157 RSUs granted in connection with the Company’s IPO vested, of which 18,001 were held by Company employees. Based on the closing price of $3.75 on October 3, 2022, the Company recorded a tax liability of $16,000 for the employees and a corresponding tax liability for the Company of $2,000. In total, the Company paid $18,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 4,204 shares of Class A Common Stock owned by the Company’s employees upon vesting. The shares withheld are available for reissuance pursuant to the 2021 Incentive Plan. On July 1, 2022, a total of 20,158 RSUs granted in connection with the Company’s IPO vested, of which 18,002 were held by Company employees. Based on the closing price of $5.94 on July 1, 2022, the Company recorded a tax liability of $26,000 for the employees and a corresponding tax liability for the Company of $2,000. In total, the Company paid $28,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 4,726 shares of Class A Common Stock owned by the Company’s employees upon vesting. The shares withheld are available for reissuance pursuant to the 2021 Incentive Plan. On June 22, 2022, a total of 27,854 RSUs were granted to the Company’s former Chief Executive Officer, Geoff Green, in exchange for $170,000 of compensation, as agreed upon in connection with his separation. On June 3, 2022, a total of 26,666 RSUs that previously had been granted to our Chief Financial Officer and General Counsel vested. RSUs are taxable upon vesting based on the market value on the date of vesting. The Company is required to make mandatory tax withholding for the payment and satisfaction of income tax, social security tax, payroll tax, or payment on account of other tax related to withholding obligations that arise by reason of vesting of an RSU. The taxable income is calculated by multiplying the number of vested RSUs for each individual by the closing share price as of the vesting date ($8.73 on June 3, 2022) and a tax liability is calculated based on each individual’s tax bracket. As a result, on June 3, 2022, the Company recorded a tax liability of $55,000 for the employees and a corresponding tax liability for the Company of $2,000. In total, the Company paid $57,000 for employee and employer taxes resulting from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 6,254 shares of Class A Common Stock owned by the Company’s employees upon vesting. The shares withheld are available for reissuance pursuant to the 2021 Incentive Plan. On April 4, 2022, a total of 1,167 RSUs that previously had been granted to our Chief Medical Officer vested. Based on the closing price of $12.85 on April 3, 2022, the Company recorded a tax liability of $5,000 for the employee and a corresponding tax liability for the Company of $1,000. In total, the Company paid $6,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 357 shares of Class A Common Stock owned by the Chief Medical Officer upon vesting. The shares withheld are available for reissuance pursuant to the 2021 Incentive Plan. On April 1, 2022, a total of 31,016 RSUs granted in connection with the Company’s IPO vested, of which 26,360 were held by Company employees. Based on the closing price of $15.61 on April 1, 2022, the Company recorded a tax liability of $105,000 for the employees and a corresponding tax liability for the Company of $14,000. In total, the Company paid $119,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 6,222 shares of Class A Common Stock owned by the Company’s employees upon vesting. The shares withheld are available for reissuance pursuant to the 2021 Incentive Plan. On April 1, 2022, a total of 2,500 RSUs vested that were previously granted to a member of the Company’s Board of Directors vested. On February 12, 2022, a total of 8,750 RSUs that were previously granted to members of the Company’s Board of Directors upon the completion of the IPO vested. On January 3, 2022, a total of 35,246 RSUs granted in connection with the Company’s IPO vested, of which 29,614 were held by Company employees. Based on the closing price of $12.09 on January 3, 2022, the Company recorded a tax liability of $92,000 for the employees and a corresponding tax liability for the Company of $14,000. In total, the Company paid $106,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 10,627 shares of Class A Common Stock owned by the Company’s employees upon vesting. The shares withheld are available for reissuance pursuant to the 2021 Incentive Plan. During the year ended December 31, 2021, and prior to the Corporate Conversion, the Company issued 1,130 Series C Common Membership Units (“Series C Units”), as payment for existing consulting agreements, with an aggregate value of $0.1 million. As part of the Corporate Conversion, 62,764 outstanding Series C units (which includes the units referenced in the prior sentence) converted into 338,030 shares of Class A Common Stock. Also, during the year ended December 31, 2021, the Company issued 61,379 and 110,387 unregistered shares of Class A Common Stock, with an aggregate value of less than $0.5 million and $0.8 million, respectively, as payment under consulting and license agreements. During the year ended December 31, 2022, 374 stock options were exercised for Class A Common Stock shares at an average exercise price of $5.73 for $2,143. During the year ended December 31, 2021, 1,812 stock options were exercised for Class A Common Stock shares at an average exercise price of $5.73 for $10,383. Also, during the year ended December 31, 2021, 51,061 warrants were exercised for Class A Common Stock shares at an exercise price of $12.00 for $612,732. On October 1, 2021, a total of 35,256 RSUs granted to employees and directors vested, of which 33,022 were held by Company employees. Based on the closing price of $3.65 on October 1, 2021, the Company recorded a tax liability of $452,000 for the employees and a corresponding tax liability for the Company of $38,000. In total, the Company paid $489,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 123,662 Class A Common Stock shares owned by the Company’s employees upon vesting. The shares withheld are available for reissuance pursuant to the 2021 Incentive Plan. Class B Common Stock In connection with the Corporate Conversion, 2,000,000 outstanding Series A and B units were converted into 15,702,834 shares of our unregistered Class B Common Stock. Holders of Class A Common Stock generally have rights identical to holders of Class B Common Stock, except that holders of Class A Common Stock are entitled to one vote per share and holders of Class B Common Stock are entitled to five (5) votes per share. The holders of Class B Common Stock may convert each share of Class B Common Stock into one share of Class A Common Stock at any time at the holder’s option. Class B Common Stock is not publicly tradable. During the year ended December 31, 2022, shareholders exchanged 811,749 shares of Class B Common Stock for 811,749 shares of Class A Common Stock. Warrants As part of the IPO, the underwriter received warrants to purchase 106,400 shares of Class A Common Stock. The warrants are exercisable at any time and from time to time, in whole or in part, during the four and a half-year period commencing August 12, 2021, at a price of $12.00 per share. Total grant date fair value of warrants as of December 31, 2021 was approximately $0.5 million. During 2021, the underwriters assigned 95,760 of the warrants to its employees. As of December 31, 2021, 51,061 warrants have been exercised for Class A Common Stock shares at an exercise price of $12.00 for $612,732. As part of the 2021 PIPE Offering, the Company issued 1,169,288 warrants to investors to purchase up to a number of shares of Class A Common Stock equal to the number of shares of Class A Common Stock purchased by such investor in the offering, at an exercise price of $17.50 per share. The purchaser warrants are immediately exercisable, expire five years from the date of issuance and have certain downward pricing adjustment mechanisms, subject to a floor, as set forth in greater detail in the purchase warrants. In addition, the Company granted the underwriters warrants, under similar terms, to purchase 46,722 shares of Class A Common Stock, at an exercise price of $17.50 per share. Prior Period Members’ Equity Series A Units Series B Units Series C Units Number of Amount Number of Amount Number of Amount Balance at December 31, 2019 1,000,000 $ 250 1,000,000 $ 1,832 43,695 $ 2,513 Series C units issued for cash - - - - 18,335 1,100 Issuance of Series C units as payment for amounts accrued - - - - 734 44 Equity-based compensation - - - - - 39 Balance at December 31, 2020 1,000,000 $ 250 1,000,000 $ (1,777 ) 62,764 $ 3,584 Series A Units Series B Units Series C Units Number of Amount Number of Amount Number of Amount Balance at December 31, 2020 1,000,000 $ 250 1,000,000 $ (1,777 ) 62,764 $ 3,584 Conversion of Units into Class A and B common stock (1,000,000 ) (250 ) (1,000,000 ) 1,777 (62,764 ) (3,584 ) Balance at December 31, 2021 - $ - - $ - - $ -

Equity Incentive Plan

Equity Incentive Plan	12 Months Ended
	Dec. 31, 2022
Equity Incentive Plan [Abstract]
Equity Incentive Plan	8. Equity Incentive Plan RSUs As part of the Company’s IPO, the Company adopted and approved the 2021 Incentive Award Plan (“2021 Incentive Plan”). Under the 2021 Incentive Plan, the Company may grant cash and equity incentive awards to eligible service providers in order to attract, motivate and retain the talent for which the Company competes. On November 16, 2022, the Company accounted for but had not issued 48,140 RSUs convertible to unregistered shares of Class A Common Stock, with an aggregate value of $207,000 as payment for accrued expenses under a consulting agreement with Dr. Hare. On September 6, 2022, the Company granted Mr. Bailey an equity incentive award of 20,000 RSUs. The RSUs will vest 25% upon the first-year anniversary of his first day of employment with Longeveron, with 25% vesting thereafter on the second, third and fourth anniversaries of his employment. In each case, the vesting of the equity awards will be subject to Mr. Bailey’s continued service through the applicable vesting dates. RSUs shall be expensed on a quarterly basis at the rate of $5,838 for the quarterly vesting amount of 1,250 RSUs, with a price per share of $4.67 (the closing price of the Company’s stock on September 6, 2022). On June 22, 2022, the Company granted $170,000 of separation compensation to Mr. Green (Mr. Green resigned as CEO effective June 1, 2022), which were converted into 27,854 RSUs. The RSU were issued based on the three-day average of the fair market value prior to the time of grant, June 22, 2022, of $6.10. On June 3, 2022, the Company granted a bonus to each of Mr. Clavijo and Mr. Lehr in the form of RSUs. Mr. Clavijo and Mr. Lehr were each granted 40,000 RSUs each that vested one-third at the grant date, with the remaining two thirds vesting on the first- and second-year anniversary of the grant date. The RSU were issued based at fair market value at the time of grant, June 3, 2022, of $8.73. On April 4, 2022, the Company appointed K. Chris Min, M.D., Ph.D. as its Chief Medical Officer. Dr. Min’s employment agreement provides for annual base salary of $350,000, and he will be eligible to receive a performance bonus equal to 30% of his base salary, prorated for his first year of employment. Dr. Min received a $60,000 signing bonus, with 50% of this amount paid in RSUs and 50% in stock options. Dr. Min also received two equity incentive awards: 150,000 RSUs and a stock option award exercisable for 50,000 shares. Each award will vest 25% upon the first-year anniversary of his first day of employment with Longeveron, with 25% vesting thereafter on the second, third and fourth anniversaries of his employment. In each case, the vesting of the equity awards will be subject to Dr. Min’s continued service through the applicable vesting dates. RSUs shall be expensed on a quarterly basis at the rate of $0.1 million for the quarterly vesting amount of 9,375 RSUs, with a price per share of $12.85 (the closing price of the Company’s stock on April 4, 2022). Stock options shall be expensed based upon a Black-Scholes calculation, the price per share to be expensed was $11.34 and a total cost of $0.6 million would be expensed ratably over 48 months. On July 20, 2021, the Company granted a bonus for the completion of the IPO to Mr. Green, Mr. Lehr and Dr. Hare of $100,000, $75,000 and $75,000, respectively. The bonus was paid out in cash and RSUs with Mr. Green, Mr. Lehr and Dr. Hare receiving 8,223, 6,167 and 12,335 RSUs each, respectively. The RSU were issued based on a fair market value at the time of grant, July 20, 2021, of $6.08. As of December 31, 2022 and 2021, the Company had 329,746 and 196,751, respectively RSUs outstanding (unvested). RSU activity for the year ended December 31, 2022 was as follows: Number of RSUs Outstanding at December 31, 2021 196,751 RSU granted 333,329 RSUs vested (162,031 ) RSU expired/forfeited (38,304 ) Outstanding (unvested) at December 31, 2022 329,746 Stock Options Stock options may be granted under the 2021 Incentive Plan. The exercise price of options is equal to the fair market value of the Company’s Class A Common Stock as of the grant date. Options historically granted have generally become exercisable over four years and expire ten years from the date of grant. The 2021 Incentive Plan provides for equity grants to be granted up to 5% of the outstanding common stock shares. The fair value of the options issued are estimated using the Black-Scholes option-pricing model and have the following assumptions: a dividend yield of 0%; an expected life of 10 years; volatility of 95%; and risk-free interest rate based on the grant date ranging from of 1.23% to 3.68%. Each option grant made during 2022 and 2021, will be expensed ratably over the option vesting periods, which approximates the service period. As of December 31, 2022, the Company has recorded issued and outstanding options to purchase a total of 470,191 shares of Class A Common Stock pursuant to the 2021 Incentive Plan, at a weighted average exercise price of $6.18 per share. Also, as of December 31, 2021, the Company has recorded issued and outstanding options to purchase a total of 304,449 shares of Class A Common Stock pursuant to the 2021 Incentive Plan, at a weighted average exercise price of $5.96 per share. For the year ended December 31, 2022: Number of Stock options vested (based on ratable vesting) 151,258 Stock options unvested 318,933 Total stock options outstanding at December 31, 2022 470,191 For the year ended December 31, 2021: Number of Stock options vested (based on ratable vesting) 59,773 Stock options unvested 244,676 Total stock options outstanding at December 31, 2021 304,449 Stock Option activity for the year ended December 31, 2022 was as follows: Number of Weighted Average Outstanding at December 31, 2021 304,449 $ 5.96 Options granted 242,003 $ 8.16 Options exercised (374 ) $ 5.73 Options expired/forfeited (75,887 ) $ 6.08 Outstanding at December 31, 2022 470,191 $ 7.07 On December 21, 2022, the Company granted an award of 5,000 Class A Common Stock options to each of its directors (a total of 45,000). The stock option award has a four-year vesting period, vesting 25% per year, and has an exercise price of $3.00. Based upon a Black-Scholes calculation, the price per share to be expensed was $2.67 and a total cost of $135,000 that would be expensed ratably over 48 months. On November 16, 2022, the Company granted an award of 22,843 Class A Common Stock options to Mr. Lehr. The stock option award has a four-year vesting period, vesting 25% per year, and has an exercise price of $4.30. Based upon a Black-Scholes calculation, the price per share to be expensed was $2.94 and a total cost of less than $0.1 million would be expensed ratably over 48 months. On September 6, 2022, the Company granted an award of 10,000 Class A Common Stock options to an employee. The stock option award has a four-year vesting period, vesting 25% per year, and has an exercise price of $4.67. Based upon a Black-Scholes calculation, the price per share to be expensed was $4.15 and a total cost of less than $0.1 million would be expensed ratably over 48 months. On June 3, 2022, the Company granted an award of 5,000 Class A Common Stock options to Mr. Lehr. The stock option award vested upon the grant date and has an exercise price of $8.73. Based upon a Black-Scholes calculation, the price per share to be expensed was $7.73 and a total cost of less than $0.1 million was expensed on the grant date. On March 14, 2022, the Company granted an award of 22,000 Class A Common Stock options to employees. The stock option award has a four-year vesting period, vesting 25% per year, and has an exercise price of $5.94. Based upon a Black-Scholes calculation, the price per share to be expensed was $5.23 and a total cost of less than $0.1 million would be expensed ratably over 48 months. On January 6, 2022, the Company granted awards of 84,825 Class A Common Stock options to employees. The stock option awards have four-year vesting periods, vesting 25% per year, and have an exercise price of $10.00. Based upon a Black-Scholes calculation, the price per share to be expensed was $8.78 and a total cost of $0.7 million would be expensed ratably over 48 months. On April 22, 2021, the Company granted awards of 64,125 Class A Common Stock options to employees. The stock option awards have four-year vesting periods, vesting 25% per year, and have an exercise price of $5.73. Based upon a Black-Scholes calculation, the price per share to be expensed was $5.03 and a total cost of $0.3 million would be expensed ratably over 48 months. On May 5, 2021, the Company granted an award of 10,000 Class A Common Stock options to an employee. The stock option award has a four-year vesting period, vesting 25% per year, and has an exercise price of $5.89. Based upon a Black-Scholes calculation, the price per share to be expensed was $5.17 and a total cost of less than $0.1 million would be expensed ratably over 48 months. On May 17, 2021, the Company granted an award of 30,000 Class A Common Stock options to an employee. The stock option award has a four-year vesting period, vesting 25% per year, and has an exercise price of $5.29. Based upon a Black-Scholes calculation, the price per share to be expensed was $4.64 and a total cost of approximately $0.1 million would be expensed ratably over 48 months. On June 1, 2021, the Company granted an award of 5,000 Class A Common Stock options to an employee. The stock option award has a four-year vesting period, vesting 25% per year, and has an exercise price of $6.77. Based upon a Black-Scholes calculation, the price per share to be expensed was $5.94 and a total cost of less than $0.1 million would be expensed ratably over 48 months. On July 20, 2021, the Company granted 225,000 Class A Common Stock options to executives. Mr. Green was granted 75,000 Class A Common Stock options and Mr. Lehr, Dr. Hare and Mr. Clavijo were each granted 50,000 Class A Common Stock options. The stock options have four-year vesting periods, vesting 12.5% on July 22, 2021 with the remaining award vesting in equal installments over the remaining four years, with an exercise price of $6.08. Based upon a Black-Scholes calculation, the price per share to be expensed was $5.32 and a total cost of $1.2 million would be expensed ratably over 48 months. For the years ended December 31, 2022 and 2021, the equity-based compensation expense amounted to approximately $2.3 million and $6.4 million, respectively, which is included in the research and development and general and administrative expenses in the statements of operations for the years ended December 31, 2022 and 2021. As of December 31, 2022, the remaining unrecognized equity-based compensation (which includes RSUs and stock options) of approximately $2.9 million will be recognized over approximately a weighted average of 4.0 years.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies Master Services and Clinical Studies Agreements: As of December 31, 2022, the Company had two active master services agreements with third parties to conduct its clinical trials and manage clinical research programs and clinical development services on behalf of the Company. The Company expects these agreements or amended current agreements to have total expenditures of approximately $2.9 million over the next two years. On March 10, 2022, the Company entered into a clinical studies agreement with a third party in conjunction with an upcoming clinical trial in Japan. The agreement provides for payments totaling $1.0 million over the course of two years. As of December 31, 2021, the Company had two active master services agreements with third parties to conduct its clinical trials and manage clinical research programs and clinical development services on behalf of the Company. Consulting Services Agreement: On November 20, 2014, the Company entered into a ten-year consulting services agreement with Dr. Joshua Hare, its CSO. Under the agreement, the Company has agreed to pay the CSO $265,000 annually. The compensation payments are for scientific knowledge, medical research, technical knowledge, skills, and abilities to be provided by the CSO to further develop the intellectual property rights assigned by the CSO to the Company. This agreement requires the CSO to also assign to the Company the exclusive right, title, and interest in any work product developed from his efforts during the term of this agreement. On November 16, 2022, the Company accounted for but had not issued 48,140 RSUs convertible to unregistered shares of Class A Common Stock, with an aggregate value of $207,000 as payment for accrued expenses under a consulting agreement with the CSO. As of December 31, 2022, the Company had an accrued balance due to the CSO of approximately $22,000 and as of December 31, 2021 had a balance due of $164,000. Technology Services Agreement: On March 27, 2015, the Company entered into a technology services agreement with Optimal Networks, Inc. (a related company owned by a Dr. Joshua Hare’s brother-in-law) for use of information technology services. The Company agreed to issue the related party equity incentive units in the amount equal to 50% of the charges for invoiced services, with such equity to be issued annually on or about the anniversary date of the agreement. During 2017, the Company issued 1,901 Series C Units, and on November 22, 2019, and January 29, 2021, the Company issued 820 and 410 Series C Units, respectively, as payment for an aggregate of $0.2 million of accrued technology services. The Series C units were converted to 16,755 Class A common stock shares. As of December 31, 2022 and 2021, the Company owed less than $0.1 million, pursuant to this agreement, which is included in accounts payable in the December 31, 2022 and 2021 balance sheets. Exclusive Licensing Agreements: UM Agreement On November 20, 2014, the Company entered into an Exclusive License Agreement with UM for the use of certain Aging-related frailty-related MSC technology rights developed by our Chief Science Officer at UM. The UM License is a worldwide, exclusive license, with right to sublicense, with respect to any and all know-how specifically related to the development of the culture-expanded MSCs for aging-related frailty used at the IMSCs, all SOPs used to create the IMSCs, and all data supporting isolation, culture, expansion, processing, cryopreservation and management of the IMSCs. The Company is required to pay UM (i) a license issue fee of $5,000, (ii) a running royalty in an amount equal to three percent of annual net sales on products or services developed from the technology, payable on a country-by-country basis beginning on the date of first commercial sale through termination of the UM License Agreement, and which may be reduced to the extent we are required to pay royalties to a third party for the same product or process, (iii) escalating annual cash payments of up to fifty thousand dollars, subject to offset. The agreement extends for up to 20 years from the last date a product or process is commercialized from the technology and was amended in 2017 to modify certain milestone completion dates as detailed below In 2021 the license fee was increased by an additional $100,000, to defray patent costs. In addition, the Company issued 110,387 unregistered shares of Class A Common Stock to UM. The milestone payment amendments shifted the triggering payments to three payments of $500,000, to be paid within six months of: (a) the completion of the first Phase 3 clinical trial of the products (based upon the final data unblinding); (b) the receipt by the Company of approval for the first new drug application (“NDA”), biologics application (“BLA”), or other marketing or licensing application for the product; and (c) the first sale following product approval. “Approval” refers to Product approval, licensure, or other marketing authorization by the U.S. Food and Drug Administration, or any successor agency. The amendments also provided for the Company’s license of additional technology, to the extent not previously included in the UM License, and granted the Company an exclusive option to obtain an exclusive license for (a) the HLHS IND with ckit+ cells; and (b) UMP-438 titled “Method of Determining Responsiveness to Cell Therapy in Dilated Cardiomyopathy.” The Company has the right to terminate the UM License upon 60 days’ prior written notice, and either party has the right to terminate upon a breach of the UM License. To date, the Company has made payments totaling $140,000 to UM, and as of December 31, 2022, we had accrued $50,000 in milestone fees payable to UM and $100,000 for patent related reimbursements based on the estimated progress to date. CD271 On December 22, 2016, the Company entered into an exclusive license agreement with an affiliated entity of Dr. Joshua Hare, JMHMD, for the use of CD271 cellular therapy technology. The Company recorded the value of the cash consideration and membership units issued to obtain this license agreement as an intangible asset. The Company is required to pay as royalty, 1% of the annual net sales of the licensed product(s) used, leased, or sold by or for licensee or its sub-licensees. If the Company sublicenses the technology, it is also required to pay an amount equal to 10% of the net sales of the sub-licensees. In addition, on December 23, 2016, as required by the license agreement, the Company paid an initial fee of $250,000 to JMHMD, and issued to it 10,000 Series C Units, valued at $250,000. The $0.5 million of value provided to JMHMD for the license agreement, along with professional fees of approximately $27,000, were recorded as an intangible asset that is amortized over the life of the license agreement which was defined as 20 years. Further, expenses related to the furtherance of the CD271+ technology is being capitalized and amortized as incurred over 20 years. There were no license fees due for the years ended December 31, 2022 and 2021 pertaining to this agreement. Other Royalty Under the grant award agreement with the Alzheimer’s Association, the Company may be required to make revenue sharing or distribution of revenue payments for products or inventions generated or resulting from this clinical trial program. The potential payments, although not currently defined, could result in a maximum payment of five times (5x) the award amount. Contingencies – Legal On September 13, 2021, the Company and certain of our directors and officers were named as defendants in a securities lawsuit filed in the U.S. District Court for the Southern District of Florida and brought on behalf of a purported class. The suit alleges there were materially false and misleading statements made (or omissions of required information) in the Company’s initial public offering materials and in other disclosures during the period from our initial public offering on February 12, 2021, through August 12, 2021, in violation of the federal securities laws. The action seeks damages on behalf of a proposed class of purchasers of our Common Stock during said period. The Company entered into an agreement in principle with the plaintiffs to settle the litigation for $1.4 million. The settlement agreement is subject to final approval by the Court, which we expect to occur sometime in 2023. This amount is recorded as Non-operating Lawsuit expenses. Legal expenses incurred in ordinary business activities are reported within general and administrative expenses. Contingencies – COVID-19 Pandemic The Company continues to monitor new developments on how the COVID-19 pandemic is affecting the Company’s employees, business, and clinical trials. During the initial stages associated with the spread of COVID-19, the Company instructed all employees who could perform their essential employment duties from home to do so. The Company’s laboratory scientists, cell-processing scientists and other manufacturing personnel continued to work from its cGMP facility and headquarters on a day-to-day basis, and as such, cell production was minimally impacted. Certain other employees continue to maintain a fully remote or “hybrid” work arrangement as their roles allow. When the pandemic began to emerge in the U.S., most of the Company’s ongoing clinical trials had completed enrollment. However, a few subjects that were on-study and in follow-up experienced difficulties in adhering to the protocol visit schedule. Because the Company primarily enrolls older adults in its trials, who are at particular risk for poor outcomes related to COVID-19 infection, the Company experienced some disruption in executing the follow-up visits in its studies. These disruptions resulted in challenges that included temporary clinical site closures, the inability to leave a residence due to regional “stay-at-home” orders and an unwillingness of trial subjects to leave their residence to visit the hospital or clinic. To minimize and mitigate these disruptions, the Company conducted remote visits (via telemedicine), arranged for in-home visits for phlebotomy in order to collect blood samples and other protocol-specific assessments, and amended protocols to increase the window of time for follow-up visits. Despite these efforts, several subjects missed follow-up visits, had their follow up visit outside of the protocol-defined time-window, or withdrew from the trial prior to completion. Regardless, given the steps implemented by Longeveron, the cumulative instances were few and did not appear to have a material impact on its now-completed Phase 2b Aging-related frailty study, Phase 1 Vaccine trial, Phase 1 Alzheimer’s disease trial, and Phase 1 HLHS clinical trial.

Employee Benefits Plan

Employee Benefits Plan	12 Months Ended
	Dec. 31, 2022
Employee Benefits Plan [Abstract]
Employee Benefits Plan	10. Employee Benefits Plan The Company sponsors a defined contribution employee benefit plan (the “Plan”) under the provisions of Section 401(k) of the Internal Revenue Code. The Plan covers substantially all full-time employees of the Company who have completed one year of service. Contributions to the Plan by the Company are at the discretion of the Board of Directors. The Company contributed approximately $88,000 and $66,000 to the Plan during the years ended December 31, 2022 and 2021, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax [Abstract]
Income Taxes	11. Income Taxes The tax effects of temporary differences and net operating loss (“NOL”) carryforwards that gave rise to significant portions of the deferred tax assets and deferred tax liabilities were approximately as follows at December 31, 2022 and December 31, 2021 (the Company did not have deferred tax assets or liabilities as of December 31, 2020 as it was just incorporated in 2021): 2022 2021 Deferred tax assets: Net operating loss carry forwards $ 6,103,000 $ 2,250,000 ASC842 Lease liability 690,000 3,142,000 Equity based compensation 1,993,000 1,641,000 Fixed assets 435,000 - Intangible assets 45,000 - Capitalized research & development expenses 1,753,000 - Accrual to cash adjustment 911,000 240,000 Total deferred tax assets 11,930,000 7,273,000 Valuation allowance (11,524,000 ) (5,665,000 ) Deferred tax assets, net of valuation allowance 406,000 1,608,000 Deferred tax liabilities: ASC842 Right-of-use asset (406,000 ) (1,813,000 ) Changes in other assets - 227,000 Depreciation and amortization - (22,000 ) Total deferred tax liabilities (406,000 ) (1,608,000 ) Deferred tax assets and liabilities, net of valuation allowance $ - $ - As of December 31, 2022, the Company had NOL carryforwards for federal purposes of approximately $23 million, all of which have no expiration. The Company also had state NOL carryforwards of approximately $22.8 million, which expire at various dates through 2043. However, these NOLs are subject to various limitations under Internal Revenue Code (“IRC”) Section 382. IRC Section 382 limits the use of NOLs to the extent there has been an ownership change of more than 50 percentage points in shares owned by any 50% owner. In addition, the NOL carry forwards are subject to examination by the taxing authority and could be adjusted or disallowed due to such exams. Although the Company has not undergone an IRC Section 382 analysis, it is likely that the utilization of the NOLs may be substantially limited. Reconciliations of the difference between income tax benefit computed at the federal and state statutory tax rates and the provision for income tax benefit for the years ended December 31, 2022 and 2021 were as follows: 2022 2021 Federal tax at statutory rate 21.0 % 21.0 % State tax benefits, net of federal benefit 6.9 3.7 Other 0.8 3.0 Change in valuation allowance (28.7 ) (27.7 ) Income tax benefit - % - % Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of December 31, 2022, there were no uncertain positions. The Company’s U.S. federal and state net operating losses have occurred since its inception and as such, tax years subject to potential tax examination could apply from 2021, the earliest year with a net operating loss carryover, because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities. Interest and penalties, if any, as they relate to income taxes assessed, are included in the income tax provision. The Company did not have any unrecognized tax benefits and has not accrued any interest or penalties for the years ended December 31, 2022 and 2021.

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2022
Loss Per Share [Abstract]
Loss Per Share	12. Loss Per Share Basic and diluted net loss per share have been computed using the weighted-average number of shares of common stock outstanding during the period. We have outstanding stock-based awards that are not used in the calculation of diluted net loss per share because to do so would be anti-dilutive. The following instruments (in thousands) were excluded from the calculation of diluted net loss per share because their effects would be antidilutive: December 31, 2022 2021 RSUs 330 197 Stock options 470 304 Warrants 1,271 1,271 Total 2,071 1,772

Reclassification of Prior Year

Reclassification of Prior Year Presentation	12 Months Ended
	Dec. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Reclassification of Prior Year Presentation	13. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. An adjustment has been made to the Statement of Operations for the Years Ended December 31, 2021. During 2021, $1.0 million in expenses related to investor and public relations had been recorded as general and administrative expenses rather that in selling and marketing expenses. This change in classification does not affect previously reported operation expenses in the Statement of Operations.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events On January 3, 2023, previously disclosed RSUs granted to employees and directors vested. A total of 20,161 RSUs vested of which 18,005 were held by Company employees. RSUs are taxable upon vesting based on the market value on the date of vesting. The Company is required to make mandatory tax withholding for the payment and satisfaction of income tax, social security tax, payroll tax, or payment on account of other tax related to withholding obligations that arise by reason of vesting of an RSU. The taxable income is calculated by multiplying the number of vested RSUs for each individual by the $3.37 closing price as of the vesting date (January 3, 2022) and a tax liability is calculated based on each individual’s tax bracket. As a result, on January 3, 2022, the Company recorded a tax liability of $15,000 for the employees and a corresponding tax liability for the Company of $2,000. In total, the Company paid $17,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 4,431 shares of Class A Common Stock owned by the Company’s employees upon vesting. The shares received have been transferred into the 2021 Incentive Plan. On February 22, 2023, the Board of Directors of Longeveron Inc. (the “Company”) appointed Mr. Mohamed Wa’el Ahmed Hashad to serve as the Company’s Chief Executive Officer, effective March 1, 2023. Mr. Hashad will also join the Company’s Board of Directors at such time as such appointment may be accomplished without violating any requirements under Nasdaq. Dr. Chris Min, who has been serving as interim Chief Executive Officer, will continue to serve as Chief Medical Officer. In connection with his appointment as Chief Executive Officer, the Company and Mr. Hashad entered into a Letter Agreement effective as of March 1, 2023 (the “Agreement”). Under the terms of the Agreement, Mr. Hashad will receive an annual salary of $530,000 and will be eligible for an annual cash bonus of up to seventy percent (70%) of his base salary, eighty percent (80%) of which will be based on the achievement of pre-established performance criteria and twenty percent (20%) of which will be discretionary. Mr. Hashad will receive a signing bonus of 50,000 Restricted Stock Units, which shall vest in quarterly installments on each of April 1, 2023, July 1, 2023, September 1, 2023, and December 31, 2023. Mr Hashad will also be eligible to receive annual long-term equity incentive awards through 2026 consisting of 50,000 shares of time-based vesting stock options and up to 125,000 of performance share units, in accordance with the terms of the Longeveron 2021 Incentive Award Plan.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Use of estimates	Use of estimates: The presentation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Accounting Standard Updates	Accounting Standard Updates In December 2019, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2019-12, “Income Taxes (Topic 740)”. The amendments in this ASU simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and by clarifying and amending other areas of Topic 740. The amendments in this ASU are effective for annual and interim periods beginning after December 15, 2020. We adopted this ASU on January 1, 2021 with no material impact on our financial statements. A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any, that the implementation of such proposed standards would have on the Company’s financial statements.
Cash and cash equivalents	Cash and cash equivalents: The Company considers cash to consist of cash and cash equivalents and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.
Marketable Securities	Marketable Securities: Marketable securities at December 31, 2022 and 2021 consisted of marketable fixed income securities, primarily corporate bonds, as well as U.S. Government and agency obligations which are categorized as trading securities and are thus marked to market and stated at fair value in accordance with ASC 820 Fair Value Measurement Investments in Debt and Equity Securities
Inventory	Inventory: The Company will begin carrying inventory of its biological products on its balance sheets following commercial launch of such products. Inventory will consist of raw materials, biological products in process, and finished goods available for sale. The Company will determine its inventory values using the average cost method. Inventory will be valued at the lower of cost or net realizable value and will exclude units that the Company anticipates distributing for clinical evaluation. As of each of December 31, 2022 and 2021, all of the Company’s biological products were anticipated to be distributed for clinical evaluation. The Company does not currently carry any inventory for its biological products, as it has yet to launch a product for commercial distribution. Historically the Company’s operations have focused on clinical trials and discovery efforts, and accordingly, costs of manufactured clinical doses of biological product candidates were expensed as incurred, consistent with the accounting for all other research and development costs. Once the Company begins commercial distribution, costs of all newly manufactured biological products will be allocated either for use in commercial distribution, which will be carried as inventory and not expensed, or for research and development efforts, which will continue to be expensed as incurred.
Accounts and grants receivable	Accounts and grants receivable: Accounts and grants receivable include amounts due from customers, granting institutions and others. The amounts as of December 31, 2022 and 2021 are deemed to be collectible and no amount has been recognized for doubtful accounts. MSCRF-TEDCO (defined below under Revenue Recognition) generally advance grant funds and therefore a receivable is not usually recognized. In addition, for the Clinical trial revenue, most participants pay in advance of treatment. Advanced grant funds and prepayments for the Clinical trial revenue are recorded to deferred revenue. Accounts and grants receivable by source, as of (in thousands): December 31, 2022 2021 National Institutes of Health – Grant $ 218 $ 55 Total $ 218 $ 55
Deferred offering costs	Deferred offering costs: The Company recorded certain legal, professional and other third-party fees that were directly associated with in-process equity financings as deferred offering costs until the applicable equity financing was consummated. After consummation of an equity financing, these costs are recorded in stockholders’ equity as a reduction of proceeds generated as a result of the offering. During 2021, offering costs incurred in connection with the 2021 PIPE Offering of approximately $0.2 million were netted against the proceeds from the private placement. Offering costs of $0.6 million have been prepaid as of December 31, 2020 and then netted against the IPO proceeds as of December 31, 2021.
Property and equipment	Property and equipment: Property and equipment, including improvements that extend useful lives of related assets, are recorded at cost, while maintenance and repairs are charged to operations as incurred. Depreciation is calculated using the straight-line method based on the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the original term of the lease. Depreciation expense is recorded in the research and development line of the Statement of Operations as the assets are primarily related to the Company’s clinical programs.
Intangible assets	Intangible assets: Intangible assets include payments on license agreements with the Company’s co-founder and chief scientific officer (“CSO”) and the University of Miami (“UM”) (see Note 9) and legal costs incurred related to patents and trademarks. License agreements have been recorded at the value of cash consideration, common stock and membership units transferred to the respective parties when acquired. Payments for license agreements are amortized using the straight-line method over the estimated term of the agreements, which range from 5-20 years. Patents are amortized over their estimated useful life, once issued. The Company considers trademarks to have an indefinite useful life and evaluates them for impairment on an annual basis. Amortization expense is recorded in the research and development line of the Statements of Operations as the assets are primarily related to the Company’s clinical programs.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets: The Company evaluates long-lived assets for impairment, including property and equipment and intangible assets, when events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Upon the occurrence of a triggering event, the asset is reviewed to assess whether the estimated undiscounted cash flows expected from the use of the asset plus the residual value from the ultimate disposal exceeds the carrying value of the asset. If the carrying value exceeds the estimated recoverable amounts, the asset is written down to the estimated fair value. Any resulting impairment loss is reflected on the statements of operations. Upon evaluation, management determined that there was no impairment of long-lived assets as of December 31, 2022 and 2021.
Deferred revenue	Deferred revenue: The unearned portion of advanced grant funds and prepayments for Clinical trial revenue, which will be recognized as revenue when the Company meets the respective performance obligations, has been presented as deferred revenue in the balance sheets. For the years ended December 31, 2022 and 2021, the Company recognized $0.1 million and $0, respectively, of funds that were previously classified as deferred revenue. Due to the MSCRF – TEDCO – grant ARDS program being discontinued, the $0.4 million recorded as deferred revenue will be reversed when the funds are returned to MSCRF – TEDCO.
Revenue recognition	Revenue recognition: The Company recognizes revenue when performance obligations related to respective revenue streams are met. For Grant revenue, the Company considers the performance obligation met when the grant related expenses are incurred, or supplies and materials are received. The Company is paid in tranches pursuant to terms of the related grant agreements, and then applies payments based on regular expense reimbursement submissions to grantors. There are no remaining performance obligations or variable consideration once grant expense reporting to the grantor is complete. For Clinical trial revenue, the Company considers the performance obligation met when the participant has received the treatment. The Company usually receives prepayment for these services or receives payment at the time the treatment is provided, and there are no remaining performance obligations or variable consideration once the participant received the treatment. For Contract manufacturing revenue, the Company considers the performance obligation met when the contractual obligation and / or statement of work has been satisfied. Payment terms may vary depending on specific contract terms. There are no significant judgments affecting the determination of the amount and timing of revenue recognition. Revenue by source (in thousands): Years ended 2022 2021 National Institute of Health - grant $ 164 $ 212 Clinical trial revenue 940 708 Alzheimer’s Association grant - 260 MSCRF – TEDCO 1 118 126 Contract manufacturing revenue - - Total $ 1,222 $ 1,306 1 Maryland Stem Cell Research Fund (MSCRF) - Maryland Technology Development Corporation (TEDCO) The Company records cost of revenues based on expenses directly related to revenue. For Grants, the Company records allocated expenses for Research and development costs to a grant as a cost of revenues. For the Clinical trial revenue directly related expenses for that program are expensed as incurred. These expenses are similar to those described under “Research and development expense” below.
Research and development expense	Research and development expense: Research and development costs are charged to expense when incurred in accordance with ASC 730. ASC 730 addresses the proper accounting and reporting for research and development costs. It identifies: 1) those activities that should be identified as research and development; 2) the elements of costs that should be identified with research and development activities, and the accounting for these costs; and 3) the financial statement disclosures related to them. Research and development costs include costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, property and equipment depreciation and allocation of various corporate costs. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by the third parties, patient enrollment in clinical trials, administrative costs incurred by the third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as the related services are rendered.
Concentrations of credit risk	Concentrations of credit risk: Financial instruments which potentially subject the Company to credit risk consist principally of cash and cash equivalents, marketable securities and accounts and grants receivable. Cash and cash equivalents are held in U.S. financial institutions. At times, the Company may maintain balances in excess of the federally insured amounts.
Income taxes	Income taxes: Prior to its Corporate Conversion, the Company was treated as a partnership for U.S. federal and state income tax purposes. Consequently, the Company passed its earnings and losses through to its members based on the terms of the Company’s Operating Agreement. Accordingly, no provision for income taxes is recorded in the financial statements for periods prior to the conversion. Following the Corporate Conversion, the Company’s tax provision consists of taxes currently payable or receivable, plus any change during the period in deferred tax assets and liabilities. The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In addition, a valuation allowance is established to reduce any deferred tax asset for which it is determined that it is more likely than not that some portion of the deferred tax asset will not be realized. The Company’s tax provision was $0 for the year ended December 31, 2022 and 2021 due to net operating losses. The Company has not recorded any tax benefit for the net operating losses incurred due to the uncertainty of realizing a benefit in the future. The Company recognizes the tax benefits from uncertain tax positions that the Company has taken or expects to take on a tax return. In the unlikely event an uncertain tax position exists in which the Company could incur income taxes, the Company would evaluate whether there is a probability that the uncertain tax position taken would be sustained upon examination by a taxing authority. Reserves for uncertain tax positions would then be recorded if the Company determined it is probable that either a position would not be sustained upon examination or a payment would have to be made to a taxing authority and the amount was reasonably estimable. As of December 31, 2022 and 2021, the Company does not believe it has any uncertain tax positions that would result in the Company having a liability to the taxing authority. It is the Company’s policy to expense any interest and penalties associated with its tax obligations when they are probable and estimable.
Equity-based compensation	Equity-based compensation: The Company accounts for equity-based compensation expense by the measurement and recognition of compensation expense for stock-based awards based on estimated fair values on the date of grant. The fair value of the options is estimated at the date of the grant using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the input of highly subjective assumptions, the most significant of which are the expected share price volatility, the expected life of the option award, the risk-free rate of return, and dividends during the expected term. Because the option-pricing model is sensitive to changes in the input assumptions, different determinations of the required inputs may result in different fair value estimates of the options. Neither the Company’s stock options nor its restricted stock units (“RSUs”) trade on an active market. Volatility is a measure of the amount by which a financial variable, such as a stock price, has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Given the Company’s limited historical data, the Company utilizes the average historical volatility of similar publicly traded companies that are in the same industry. The risk-free interest rate is the average U.S. treasury rate (having a term that most closely approximates the expected life of the option) for the period in which the option was granted. The expected life is the period of time that the options granted are expected to remain outstanding. Options granted have a maximum term of ten years. The Company had insufficient historical data to utilize in determining its expected life assumptions and, therefore, uses the simplified method for determining expected life.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Schedule of accounts and grants receivable	December 31, 2022 2021 National Institutes of Health – Grant $ 218 $ 55 Total $ 218 $ 55
Schedule of revenue	Years ended 2022 2021 National Institute of Health - grant $ 164 $ 212 Clinical trial revenue 940 708 Alzheimer’s Association grant - 260 MSCRF – TEDCO 1 118 126 Contract manufacturing revenue - - Total $ 1,222 $ 1,306 1 Maryland Stem Cell Research Fund (MSCRF) - Maryland Technology Development Corporation (TEDCO)

Marketable securities (Tables)

Marketable securities (Tables)	12 Months Ended
	Dec. 31, 2022
Marketable securities [Abstract]
Schedule of marketable securities	Fair Value at December 31, 2022 Level 1 Level 2 Level 3 Total U.S. Treasury obligations 96,981 - - 96,981 U.S. government agencies - 1,250,003 - 1,250,003 Corporate and foreign bonds - 7,807,655 - 7,807,655 Money market funds (1) 607,262 - - 607,262 Accrued income 64,815 - - 64,815 Total marketable securities $ 769,059 $ 9,057,658 $ - $ 9,826,717 Fair Value at December 31, 2021 Level 1 Level 2 Level 3 Total U.S. Treasury obligations 401,290 - - 401,290 U.S. government agencies - 1,424,477 - 1,424,477 Corporate and foreign bonds - 7,507,705 - 7,507,705 Money market funds (1) 576,742 - - 576,742 Accrued income 52,484 - - 52,484 Total marketable securities $ 1,030,516 $ 8,932,182 $ - $ 9,962,698 (1) Money market funds are included in cash and cash equivalents in the balance sheet.

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of major components of property and equipment	Useful Lives December 31, December 31, Leasehold improvements 10 years $ 4,328 $ 4,318 Furniture/Lab equipment 7 years 2,264 1,724 Computer equipment 5 years 46 28 Software/Website 3 years 38 38 Total property and equipment 6,676 6,108 Less accumulated depreciation and amortization 3,727 3,046 Property and equipment, net $ 2,949 $ 3,062

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Intangible assets, net [Abstract]
Schedule of major components of intangible assets	Useful Lives Cost Accumulated Total License agreements 20 years $ 2,043 $ (685 ) $ 1,358 Patent Costs 887 - 887 Trademark costs 164 - 164 Total $ 3,094 $ (685 ) $ 2,409 Useful Lives Cost Accumulated Total License agreements 20 years $ 2,043 $ (473 ) $ 1,570 Patent Costs 615 - 615 Trademark costs 149 - 149 Total $ 2,807 $ (473 ) $ 2,334
Schedule of future amortization expense	Year Ending December 31, Amount 2023 $ 224 2024 224 2025 224 2026 89 2027 62 Thereafter 535 Total $ 1,358

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Schedule of future minimum payments under the operating leases	Year Ending December 31, Amount 2023 $ 687 2024 702 2025 719 2026 735 2027 184 Total 3,027 Less: Interest (5% discount rate) 422 Present Value of Lease Liability $ 2,605

Members' Equity and Stockhold_2

Members' Equity and Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Members’ Equity and Stockholders’ Equity [Abstract]
Schedule of prior period members’ equity	Series A Units Series B Units Series C Units Number of Amount Number of Amount Number of Amount Balance at December 31, 2019 1,000,000 $ 250 1,000,000 $ 1,832 43,695 $ 2,513 Series C units issued for cash - - - - 18,335 1,100 Issuance of Series C units as payment for amounts accrued - - - - 734 44 Equity-based compensation - - - - - 39 Balance at December 31, 2020 1,000,000 $ 250 1,000,000 $ (1,777 ) 62,764 $ 3,584 Series A Units Series B Units Series C Units Number of Amount Number of Amount Number of Amount Balance at December 31, 2020 1,000,000 $ 250 1,000,000 $ (1,777 ) 62,764 $ 3,584 Conversion of Units into Class A and B common stock (1,000,000 ) (250 ) (1,000,000 ) 1,777 (62,764 ) (3,584 ) Balance at December 31, 2021 - $ - - $ - - $ -

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)	12 Months Ended
	Dec. 31, 2022
Equity Incentive Plan [Abstract]
Schedule of RSU activity	Number of RSUs Outstanding at December 31, 2021 196,751 RSU granted 333,329 RSUs vested (162,031 ) RSU expired/forfeited (38,304 ) Outstanding (unvested) at December 31, 2022 329,746
Schedule of issued and outstanding options	Number of Stock options vested (based on ratable vesting) 151,258 Stock options unvested 318,933 Total stock options outstanding at December 31, 2022 470,191 Number of Stock options vested (based on ratable vesting) 59,773 Stock options unvested 244,676 Total stock options outstanding at December 31, 2021 304,449
Schedule of stock option activity	Number of Weighted Average Outstanding at December 31, 2021 304,449 $ 5.96 Options granted 242,003 $ 8.16 Options exercised (374 ) $ 5.73 Options expired/forfeited (75,887 ) $ 6.08 Outstanding at December 31, 2022 470,191 $ 7.07

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax [Abstract]
Schedule of deferred tax assets or liabilities	2022 2021 Deferred tax assets: Net operating loss carry forwards $ 6,103,000 $ 2,250,000 ASC842 Lease liability 690,000 3,142,000 Equity based compensation 1,993,000 1,641,000 Fixed assets 435,000 - Intangible assets 45,000 - Capitalized research & development expenses 1,753,000 - Accrual to cash adjustment 911,000 240,000 Total deferred tax assets 11,930,000 7,273,000 Valuation allowance (11,524,000 ) (5,665,000 ) Deferred tax assets, net of valuation allowance 406,000 1,608,000 Deferred tax liabilities: ASC842 Right-of-use asset (406,000 ) (1,813,000 ) Changes in other assets - 227,000 Depreciation and amortization - (22,000 ) Total deferred tax liabilities (406,000 ) (1,608,000 ) Deferred tax assets and liabilities, net of valuation allowance $ - $ -
Schedule of federal and state statutory tax rates and the provision for income tax benefit	2022 2021 Federal tax at statutory rate 21.0 % 21.0 % State tax benefits, net of federal benefit 6.9 3.7 Other 0.8 3.0 Change in valuation allowance (28.7 ) (27.7 ) Income tax benefit - % - %

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Loss Per Share [Abstract]
Schedule of calculation of diluted net loss per share	December 31, 2022 2021 RSUs 330 197 Stock options 470 304 Warrants 1,271 1,271 Total 2,071 1,772

Nature of Business, Basis of _2

Nature of Business, Basis of Presentation, and Liquidity (Details) - USD ($) $ / shares in Units, $ in Millions				12 Months Ended
	Dec. 03, 2021	Mar. 15, 2021	Feb. 12, 2021	Dec. 31, 2022	Dec. 31, 2021
Nature of Business, Basis of Presentation, and Liquidity (Details) [Line Items]
Total number of share (in Shares)	1,169,288
Recurring loss				$ 18.8	$ 17
Accumulated deficit					62.8
Cash and cash equivalents					10.5
Marketable securities					$ 9.2
Initial Public Offering [Member]
Nature of Business, Basis of Presentation, and Liquidity (Details) [Line Items]
Sale of stock price, per share (in Dollars per share)			$ 10
Purchase additional shares of public offering (in Shares)			399,000
Private Placement [Member]
Nature of Business, Basis of Presentation, and Liquidity (Details) [Line Items]
Purchase price (in Dollars per share)	$ 17.5
Exercise price (in Dollars per share)	$ 17.5
Purchase price amount	$ 20.5
Class A Common Stock [Member] | Initial Public Offering [Member]
Nature of Business, Basis of Presentation, and Liquidity (Details) [Line Items]
Common Stock, par value (in Dollars per share)			$ 0.001
Sale of stock (in Shares)			2,660,000
Sale of stock price, per share (in Dollars per share)			$ 10
Aggregate gross proceeds			$ 26.6
Class A Common Stock [Member] | Over-Allotment Option [Member]
Nature of Business, Basis of Presentation, and Liquidity (Details) [Line Items]
Sale of stock (in Shares)		250,000
Sale of stock price, per share (in Dollars per share)		$ 10
Aggregate gross proceeds		$ 2.5
Class A Common Stock [Member] | Private Placement [Member]
Nature of Business, Basis of Presentation, and Liquidity (Details) [Line Items]
Exercise price (in Dollars per share)	$ 17.5
Share purchase (in Shares)	46,722

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Summary of Significant Accounting Policies (Details) [Line Items]
Deferred offering costs		$ 200,000	$ 600,000
Deferred revenue	$ 400,000
Tax provision	$ 0	0
Options granted maximum term	10 years
Minimum [Member] | Intangible Assets [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
intangible assets estimated useful life	5 years
Maximum [Member] | Intangible Assets [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
intangible assets estimated useful life	20 years
Clinical Trial Revenue [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Revenue	$ 100,000	$ 0

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of accounts and grants receivable - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts and grants receivable	$ 218	$ 55
National Institutes of Health - Grant [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts and grants receivable	$ 218	$ 55

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of revenue - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Revenue		$ 1,222	$ 1,306
National Institutes of Health - Grant [Member]
Disaggregation of Revenue [Line Items]
Revenue		164	212
Clinical trial revenue [Member]
Disaggregation of Revenue [Line Items]
Revenue		940	708
Alzheimer’s Association - Grant [Member]
Disaggregation of Revenue [Line Items]
Revenue			260
MSCRF – TEDCO - Grant [Member]
Disaggregation of Revenue [Line Items]
Revenue	[1]	118	126
Contract Manufacturing Revenue [Member]
Disaggregation of Revenue [Line Items]
Revenue
[1]Maryland Stem Cell Research Fund (MSCRF) - Maryland Technology Development Corporation (TEDCO)

Marketable securities (Details)

Marketable securities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Marketable securities [Abstract]
Accrued interest	$ 64,815	$ 52,484
Unrealized losses attributable marketable securities	$ 357,334

Marketable securities (Detail_2

Marketable securities (Details) - Schedule of marketable securities - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Marketable securities (Details) - Schedule of marketable securities [Line Items]
U.S. Treasury obligations	$ 96,981	$ 401,290
U.S. government agencies	1,250,003	1,424,477
Corporate and foreign bonds	7,807,655	7,507,705
Money market funds	607,262	576,742
Accrued income	64,815	52,484
Total marketable securities	9,826,717	9,962,698
Level 1 [Member]
Marketable securities (Details) - Schedule of marketable securities [Line Items]
U.S. Treasury obligations	96,981	401,290
U.S. government agencies
Corporate and foreign bonds
Money market funds	607,262	576,742
Accrued income	64,815	52,484
Total marketable securities	769,059	1,030,516
Level 2 [Member]
Marketable securities (Details) - Schedule of marketable securities [Line Items]
U.S. Treasury obligations
U.S. government agencies	1,250,003	1,424,477
Corporate and foreign bonds	7,807,655	7,507,705
Money market funds
Accrued income
Total marketable securities	9,057,658	8,932,182
Level 3 [Member]
Marketable securities (Details) - Schedule of marketable securities [Line Items]
U.S. Treasury obligations
U.S. government agencies
Corporate and foreign bonds
Money market funds
Accrued income
Total marketable securities

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 0.7	$ 0.7

Property and Equipment, Net (_2

Property and Equipment, Net (Details) - Schedule of major components of property and equipment - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 6,676	$ 6,108
Less accumulated depreciation and amortization	3,727	3,046
Property and equipment, net	$ 2,949	3,062
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Useful Lives	10 years
Total property and equipment	$ 4,328	4,318
Furniture/Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Useful Lives	7 years
Total property and equipment	$ 2,264	1,724
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Useful Lives	5 years
Total property and equipment	$ 46	28
Software/Website [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Useful Lives	3 years
Total property and equipment	$ 38	$ 38

Intangible Assets, Net (Details

Intangible Assets, Net (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Intangible assets, net [Abstract]
Amortization expense related to intangible assets	$ 0.2	$ 0.2

Intangible Assets, Net (Detai_2

Intangible Assets, Net (Details) - Schedule of major components of intangible assets - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Intangible Assets, Net (Details) - Schedule of major components of intangible assets [Line Items]
Cost	$ 3,094	$ 2,807
Accumulated amortization	(685)	(473)
Intangible assets	2,409	2,334
License agreements [Member]
Intangible Assets, Net (Details) - Schedule of major components of intangible assets [Line Items]
Cost	2,043	2,043
Accumulated amortization	(685)	(473)
Intangible assets	$ 1,358	$ 1,570
License agreements [Member] | Minimum [Member]
Intangible Assets, Net (Details) - Schedule of major components of intangible assets [Line Items]
Useful lives	20 years	20 years
Trademark costs [Member]
Intangible Assets, Net (Details) - Schedule of major components of intangible assets [Line Items]
Cost	$ 164	$ 149
Intangible assets	164	149
Patent Costs [Member]
Intangible Assets, Net (Details) - Schedule of major components of intangible assets [Line Items]
Cost	887	615
Intangible assets	$ 887	$ 615

Intangible Assets, Net (Detai_3

Intangible Assets, Net (Details) - Schedule of future amortization expense $ in Thousands	Dec. 31, 2022 USD ($)
Schedule of future amortization expense [Abstract]
2023	$ 224
2024	224
2025	224
2026	89
2027	62
Thereafter	535
Total	$ 1,358

Leases (Details)

Leases (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Jul. 01, 2020
Disclosure Text Block [Abstract]
Right of use asset	$ 1,500,000	$ 1,800,000
Lease liability	2,600,000	3,100,000
Lease costs	1,000,000	1,000,000
Lease period			1 year
Monthly payments			$ 10,000
Sublease income	27,000	$ 102,500
Receiving of equipment	17,000
Security deposit forfeited	$ 10,000

Leases (Details) - Schedule of

Leases (Details) - Schedule of future minimum payments under the operating leases $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Schedule of Future Minimum Payments Under the Operating Leases [Abstract]
2023	$ 687
2024	702
2025	719
2026	735
2027	184
Total	3,027
Less: Interest (5% discount rate)	422
Present Value of Lease Liability	$ 2,605

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of future minimum payments under the operating leases (Parentheticals)	Dec. 31, 2022
Schedule of Future Minimum Payments Under the Operating Leases [Abstract]
Discount rate	5%

Members' Equity and Stockhold_3

Members' Equity and Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands

1 Months Ended

12 Months Ended

Oct. 03, 2022

Sep. 06, 2022

Jul. 01, 2022

Jun. 03, 2022

Apr. 04, 2022

Apr. 01, 2022

Mar. 14, 2022

Feb. 12, 2022

Jan. 06, 2022

Jan. 03, 2022

Oct. 01, 2021

Jun. 01, 2021

May 05, 2021

Mar. 15, 2021

Feb. 12, 2021

Dec. 21, 2022

Nov. 16, 2022

Jun. 22, 2022

Jun. 20, 2021

May 17, 2021

Apr. 22, 2021

Dec. 31, 2022

Dec. 31, 2021

Dec. 03, 2021

Members' Equity and Stockholders' Equity (Details) [Line Items]

Additional shares

399,000

Private placement description

the Company completed the 2021 PIPE Offering wherein a total of 1,169,288 shares of the Company’s Class A Common Stock were issued at a purchase price of $17.50 per share, with each investor also receiving a warrant to purchase up to a number of shares of Class A Common Stock equal to the number of shares of Class A Common Stock purchased by such investor in the 2021 PIPE Offering, at an exercise price of $17.50 per share (the “Purchaser Warrants”), for a total purchase price of approximately $20.5 million (the “Offering”). The Purchaser Warrants are immediately exercisable, expire five years from the date of issuance and have certain downward pricing adjustment mechanisms, subject to a floor, as set forth in greater detail therein. In addition, the Company granted the underwriters warrants, under similar terms, to purchase 46,722 shares of Class A Common Stock at an exercise price of $17.50 per share.

Granted shares

20,157

10,000

20,158

26,666

1,167

31,016

22,000

8,750

84,825

35,246

35,256

5,000

10,000

22,843

27,854

225,000

30,000

64,125

Vested shares

18,001

18,002

26,360

29,614

33,022

Closing price per share (in Dollars per share)

$ 3.75

$ 5.94

$ 12.85

$ 15,610

$ 12.09

$ 3.65

Directors vested description

the Company recorded a tax liability of $16,000 for the employees and a corresponding tax liability for the Company of $2,000. In total, the Company paid $18,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 4,204 shares of Class A Common Stock owned by the Company’s employees upon vesting.

the Company recorded a tax liability of $26,000 for the employees and a corresponding tax liability for the Company of $2,000. In total, the Company paid $28,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 4,726 shares of Class A Common Stock owned by the Company’s employees upon vesting.

RSUs are taxable upon vesting based on the market value on the date of vesting. The Company is required to make mandatory tax withholding for the payment and satisfaction of income tax, social security tax, payroll tax, or payment on account of other tax related to withholding obligations that arise by reason of vesting of an RSU. The taxable income is calculated by multiplying the number of vested RSUs for each individual by the closing share price as of the vesting date ($8.73 on June 3, 2022) and a tax liability is calculated based on each individual’s tax bracket. As a result, on June 3, 2022, the Company recorded a tax liability of $55,000 for the employees and a corresponding tax liability for the Company of $2,000. In total, the Company paid $57,000 for employee and employer taxes resulting from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 6,254 shares of Class A Common Stock owned by the Company’s employees upon vesting. The shares withheld are available for reissuance pursuant to the 2021 Incentive Plan.

Based on the closing price of $12.85 on April 3, 2022, the Company recorded a tax liability of $5,000 for the employee and a corresponding tax liability for the Company of $1,000. In total, the Company paid $6,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 357 shares of Class A Common Stock owned by the Chief Medical Officer upon vesting.

the Company recorded a tax liability of $105,000 for the employees and a corresponding tax liability for the Company of $14,000. In total, the Company paid $119,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 6,222 shares of Class A Common Stock owned by the Company’s employees upon vesting.

the Company recorded a tax liability of $92,000 for the employees and a corresponding tax liability for the Company of $14,000. In total, the Company paid $106,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 10,627 shares of Class A Common Stock owned by the Company’s employees upon vesting.

the Company recorded a tax liability of $452,000 for the employees and a corresponding tax liability for the Company of $38,000. In total, the Company paid $489,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 123,662 Class A Common Stock shares owned by the Company’s employees upon vesting.

Compensation amount (in Dollars)

$ 170,000

Common stock shares description

Also, during the year ended December 31, 2021, the Company issued 61,379 and 110,387 unregistered shares of Class A Common Stock, with an aggregate value of less than $0.5 million and $0.8 million, respectively, as payment under consulting and license agreements. During the year ended December 31, 2022, 374 stock options were exercised for Class A Common Stock shares at an average exercise price of $5.73 for $2,143. During the year ended December 31, 2021, 1,812 stock options were exercised for Class A Common Stock shares at an average exercise price of $5.73 for $10,383. Also, during the year ended December 31, 2021, 51,061 warrants were exercised for Class A Common Stock shares at an exercise price of $12.00 for $612,732.

Voting per share description

Holders of Class A Common Stock generally have rights identical to holders of Class B Common Stock, except that holders of Class A Common Stock are entitled to one vote per share and holders of Class B Common Stock are entitled to five (5) votes per share.

Warrants exercise price per share (in Dollars per share)

$ 17.5

underwriters warrants

95,760

Warrants expire term

5 years

Warrants [Member]

Members' Equity and Stockholders' Equity (Details) [Line Items]

Fair value of warrants (in Dollars)

$ 500

IPO [Member]

Members' Equity and Stockholders' Equity (Details) [Line Items]

Shares issued

2,660,000

Public offering price per share (in Dollars per share)

$ 10

Gross proceeds (in Dollars)

$ 26,600

Class A Common Stock [Member]

Members' Equity and Stockholders' Equity (Details) [Line Items]

Common stock par value (in Dollars per share)

$ 0.001

Granted shares

5,000

Conversion of stock share issued

338,030

Shares issued

811,749

Warrants exercise price per share (in Dollars per share)

$ 17.5

Warrants exercised

51,061

Exercise price per share (in Dollars per share)

$ 12

Exercise warrants amount (in Dollars)

$ 612,732

Warrants issued to investors

1,169,288

Class A Common Stock [Member] | Warrants [Member]

Members' Equity and Stockholders' Equity (Details) [Line Items]

Shares issued

46,722

Warrants to purchase of common stock shares

106,400

Warrants exercise price per share (in Dollars per share)

$ 12

Class A Common Stock [Member] | IPO [Member]

Members' Equity and Stockholders' Equity (Details) [Line Items]

Public offering price per share (in Dollars per share)

$ 10

Class A Common Stock [Member] | Over-Allotment Option [Member]

Members' Equity and Stockholders' Equity (Details) [Line Items]

Public offering price per share (in Dollars per share)

$ 10

Sale of stock issued

250,000

Aggregate gross proceeds (in Dollars)

$ 2,500

Series C Units [Member]

Members' Equity and Stockholders' Equity (Details) [Line Items]

Additional shares issued

48,140

Aggregate value (in Dollars)

$ 100

Conversion of stock share issued

1,130

Conversion of outstanding shares

62,764

Class B Common Stock [Member]

Members' Equity and Stockholders' Equity (Details) [Line Items]

Conversion of outstanding shares

2,000,000

Conversion of outstanding shares

15,702,834

Shares issued

811,749

Board of Directors [Member]

Members' Equity and Stockholders' Equity (Details) [Line Items]

Granted shares

2,500

Consulting Agreements [Member] | Series C Units [Member]

Members' Equity and Stockholders' Equity (Details) [Line Items]

Aggregate value (in Dollars)

$ 207,000

Members' Equity and Stockhold_4

Members' Equity and Stockholders' Equity (Details) - Schedule of prior period members’ equity - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Series A Units [Member]
Members' Equity and Stockholders' Equity (Details) - Schedule of prior period members’ equity [Line Items]
Number of Units, beginning balance (in Shares)	1,000,000	1,000,000
Beginning balance	$ 250	$ 250
Series C units issued for cash
Issuance of Series C units as payment for amounts accrued
Equity-based compensation
Number of Units, Conversion of Units into Class A and B common stock (in Shares)	(1,000,000)
Conversion of Units into Class A and B common stock	$ (250)
Number of Units, ending balance (in Shares)		1,000,000
Ending balance		$ 250
Series B Units [Member]
Members' Equity and Stockholders' Equity (Details) - Schedule of prior period members’ equity [Line Items]
Number of Units, beginning balance (in Shares)	1,000,000	1,000,000
Beginning balance	$ (1,777)	$ 1,832
Series C units issued for cash
Issuance of Series C units as payment for amounts accrued
Equity-based compensation
Number of Units, Conversion of Units into Class A and B common stock (in Shares)	(1,000,000)
Conversion of Units into Class A and B common stock	$ 1,777
Number of Units, ending balance (in Shares)		1,000,000
Ending balance		$ (1,777)
Series C Units [Member]
Members' Equity and Stockholders' Equity (Details) - Schedule of prior period members’ equity [Line Items]
Number of Units, beginning balance (in Shares)	62,764	43,695
Beginning balance	$ 3,584	$ 2,513
Number of Units, Series C units issued for cash (in Shares)		18,335
Series C units issued for cash		$ 1,100
Number of Units, Issuance of Series C units as payment for amounts accrued (in Shares)		734
Issuance of Series C units as payment for amounts accrued		$ 44
Equity-based compensation		$ 39
Number of Units, Conversion of Units into Class A and B common stock (in Shares)	(62,764)
Conversion of Units into Class A and B common stock	$ (3,584)
Number of Units, ending balance (in Shares)		62,764
Ending balance		$ 3,584

Equity Incentive Plan (Details)

Equity Incentive Plan (Details) - USD ($)														1 Months Ended							12 Months Ended
	Oct. 03, 2022	Sep. 06, 2022	Jul. 01, 2022	Jun. 03, 2022	Apr. 04, 2022	Apr. 01, 2022	Mar. 14, 2022	Feb. 12, 2022	Jan. 06, 2022	Jan. 03, 2022	Oct. 01, 2021	Jun. 01, 2021	May 05, 2021	Dec. 21, 2022	Nov. 16, 2022	Jun. 22, 2022	Jul. 20, 2021	Jun. 20, 2021	May 17, 2021	Apr. 22, 2021	Dec. 31, 2022	Dec. 31, 2021
Equity Incentive Plan (Details) [Line Items]
RSUs convertible shares (in Shares)																					470,191	304,449
Aggregate value (in Dollars)															$ 207,000,000
Granted awards (in Shares)	20,157	10,000	20,158	26,666	1,167	31,016	22,000	8,750	84,825	35,246	35,256	5,000	10,000		22,843	27,854		225,000	30,000	64,125
Vest first year anniversary percentage		25%
Vest third year anniversary percentage		25%
Vest second year anniversary percentage		25%
Vest fourth year anniversary percentage		25%
Employment agreement description					the Company appointed K. Chris Min, M.D., Ph.D. as its Chief Medical Officer. Dr. Min’s employment agreement provides for annual base salary of $350,000, and he will be eligible to receive a performance bonus equal to 30% of his base salary, prorated for his first year of employment. Dr. Min received a $60,000 signing bonus, with 50% of this amount paid in RSUs and 50% in stock options. Dr. Min also received two equity incentive awards: 150,000 RSUs and a stock option award exercisable for 50,000 shares. Each award will vest 25% upon the first-year anniversary of his first day of employment with Longeveron, with 25% vesting thereafter on the second, third and fourth anniversaries of his employment. In each case, the vesting of the equity awards will be subject to Dr. Min’s continued service through the applicable vesting dates. RSUs shall be expensed on a quarterly basis at the rate of $0.1 million for the quarterly vesting amount of 9,375 RSUs, with a price per share of $12.85 (the closing price of the Company’s stock on April 4, 2022). Stock options shall be expensed based upon a Black-Scholes calculation, the price per share to be expensed was $11.34 and a total cost of $0.6 million would be expensed ratably over 48 months.
Cash (in Dollars)																						$ 10,500,000
Fair market value (in Dollars)																	$ 6,080
RSUs outstanding (in Shares)																					329,746	196,751
Outstanding common stock shares																					5%
dividend yield																					0%
Expected life																					10 years
Volatility																					95%
Directors total (in Dollars)														$ 45,000,000
Vesting period		25%					25%		25%			25%	25%	25%	25%			12.50%	25%	25%
Exercise price		$ 4.67					$ 5.94		$ 10			$ 6.77	$ 5.89	$ 3	$ 4.3				$ 5.29	$ 5.73
Calculation price		$ 4.15					$ 5.23		$ 8.78			$ 5.94	$ 5.17	$ 2.67	$ 2.94			$ 5.32	$ 4.64
Total cost (in Dollars)		$ 100,000					$ 100,000		$ 700,000			$ 100,000	$ 100,000	$ 135,000,000	$ 100,000			$ 1,200,000	$ 100,000	$ 300,000
Expensed ratably over		48 months					48 months		48 months					48 months	48 months
Vesting in equal installments																		4 years
Vesting exercise price																		$ 6.08
Equity based compensation expense (in Dollars)																					$ 2,300,000	$ 6,400,000
Unrecognized equity based compensation (in Dollars)																					$ 2,900,000
Maturity term																					4 years
Minimum [Member]
Equity Incentive Plan (Details) [Line Items]
Risk-free interest rate																					1.23%
Maximum [Member]
Equity Incentive Plan (Details) [Line Items]
Risk-free interest rate																					3.68%
Series C [Member]
Equity Incentive Plan (Details) [Line Items]
RSUs convertible shares (in Shares)															48,140
Class A Common Stock [Member]
Equity Incentive Plan (Details) [Line Items]
Granted awards (in Shares)														5,000
Issued and outstanding options (in Shares)																					470,191	304,449
Weighted average exercise price																					$ 6.18	$ 5.96
Mr. Bailey [Member]
Equity Incentive Plan (Details) [Line Items]
RSUs convertible shares (in Shares)		1,250
Granted awards (in Shares)		20,000
Quarterly basis rate (in Dollars)		$ 5,838,000
Price per share		$ 4.67
Mr. Green [Member]
Equity Incentive Plan (Details) [Line Items]
RSUs convertible shares (in Shares)																27,854
Granted awards (in Shares)																		75,000
Compensation granted shares (in Shares)																170,000
Fair market value prior grant																$ 6.1
Bonus for the completion (in Dollars)																	100,000,000
Mr. Green [Member] | Restricted Stock Units (RSUs) [Member]
Equity Incentive Plan (Details) [Line Items]
Cash (in Dollars)																	8,223,000
Mr. Clavijo [Member]
Equity Incentive Plan (Details) [Line Items]
RSUs convertible shares (in Shares)				40,000
Granted awards (in Shares)																		50,000
Fair market value prior grant				$ 8.73
Mr. Lehr [Member]
Equity Incentive Plan (Details) [Line Items]
Bonus for the completion (in Dollars)																	75,000,000
Mr. Lehr [Member] | Class A Common Stock [Member]
Equity Incentive Plan (Details) [Line Items]
Granted awards (in Shares)				5,000
Exercise price				$ 8.73
Calculation price				$ 7.73
Total cost (in Dollars)				$ 100,000
Mr. Lehr [Member] | Restricted Stock Units (RSUs) [Member]
Equity Incentive Plan (Details) [Line Items]
Cash (in Dollars)																	6,167,000
Dr. Hare [Member]
Equity Incentive Plan (Details) [Line Items]
Bonus for the completion (in Dollars)																	75,000,000
Dr. Hare [Member] | Restricted Stock Units (RSUs) [Member]
Equity Incentive Plan (Details) [Line Items]
Cash (in Dollars)																	$ 12,335,000

Equity Incentive Plan (Detail_2

Equity Incentive Plan (Details) - Schedule of RSU activity	12 Months Ended
	Dec. 31, 2022 shares
Schedule of Rsu Activity [Abstract]
Outstanding at December 31, 2021	196,751
RSU granted	333,329
RSUs vested	(162,031)
RSU expired/forfeited	(38,304)
Outstanding (unvested) at December 31, 2022	329,746

Equity Incentive Plan (Detail_3

Equity Incentive Plan (Details) - Schedule of issued and outstanding options - shares	Dec. 31, 2022	Dec. 31, 2021
Equity Incentive Plan (Details) - Schedule of issued and outstanding options [Line Items]
Total stock options granted	470,191	304,449
Stock options vested [Member]
Equity Incentive Plan (Details) - Schedule of issued and outstanding options [Line Items]
Total stock options granted	151,258	59,773
Stock options unvested [Member]
Equity Incentive Plan (Details) - Schedule of issued and outstanding options [Line Items]
Total stock options granted	318,933	244,676

Equity Incentive Plan (Detail_4

Equity Incentive Plan (Details) - Schedule of stock option activity - Stock Option Activity [Member]	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Equity Incentive Plan (Details) - Schedule of stock option activity [Line Items]
Number of Stock Options Outstanding beginning | shares	304,449
Weighted Average Exercise Price Outstanding beginning | $ / shares	$ 5.96
Number of Stock Options Options granted | shares	242,003
Weighted Average Exercise Price Options granted | $ / shares	$ 8.16
Number of Stock Option Options exercised | shares	(374)
Weighted Average Exercise Price Options exercised | $ / shares	$ 5.73
Number of Stock Option Options expired/forfeited | shares	(75,887)
Weighted Average Exercise Price Options expired/forfeited | $ / shares	$ 6.08
Number of Stock Options Outstanding ending | shares	470,191
Weighted Average Exercise Price Outstanding ending | $ / shares	$ 7.07

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Thousands		1 Months Ended				12 Months Ended
	Mar. 03, 2021	Nov. 16, 2022	Dec. 22, 2016	Mar. 27, 2015	Nov. 20, 2014	Dec. 31, 2022	Dec. 31, 2021	Jan. 29, 2021	Dec. 31, 2020	Nov. 22, 2019	Dec. 31, 2017
Commitments and Contingencies (Details) [Line Items]
Issuance of additional unregistered shares (in Shares)		48,140
Accrued expenses		$ 207,000
Incentive units				50%
Aggregate of accrued technology services											$ 200
Owed amount						$ 100	$ 100
Licensing agreement, description					The Company is required to pay UM (i) a license issue fee of $5,000, (ii) a running royalty in an amount equal to three percent of annual net sales on products or services developed from the technology, payable on a country-by-country basis beginning on the date of first commercial sale through termination of the UM License Agreement, and which may be reduced to the extent we are required to pay royalties to a third party for the same product or process, (iii) escalating annual cash payments of up to fifty thousand dollars, subject to offset. The agreement extends for up to 20 years from the last date a product or process is commercialized from the technology and was amended in 2017 to modify certain milestone completion dates as detailed below In 2021 the license fee was increased by an additional $100,000, to defray patent costs. In addition, the Company issued 110,387 unregistered shares of Class A Common Stock to UM.The milestone payment amendments shifted the triggering payments to three payments of $500,000, to be paid within six months of: (a) the completion of the first Phase 3 clinical trial of the products (based upon the final data unblinding); (b) the receipt by the Company of approval for the first new drug application (“NDA”), biologics application (“BLA”), or other marketing or licensing application for the product; and (c) the first sale following product approval. “Approval” refers to Product approval, licensure, or other marketing authorization by the U.S. Food and Drug Administration, or any successor agency. The amendments also provided for the Company’s license of additional technology, to the extent not previously included in the UM License, and granted the Company an exclusive option to obtain an exclusive license for (a) the HLHS IND with ckit+ cells; and (b) UMP-438 titled “Method of Determining Responsiveness to Cell Therapy in Dilated Cardiomyopathy.” The Company has the right to terminate the UM License upon 60 days’ prior written notice, and either party has the right to terminate upon a breach of the UM License. To date, the Company has made payments totaling $140,000 to UM, and as of December 31, 2022, we had accrued $50,000 in milestone fees payable to UM and $100,000 for patent related reimbursements based on the estimated progress to date. CD271 On December 22, 2016, the Company entered into an exclusive license agreement with an affiliated entity of Dr. Joshua Hare, JMHMD, for the use of CD271 cellular therapy technology. The Company recorded the value of the cash consideration and membership units issued to obtain this license agreement as an intangible asset.
Legal fees	$ 3					$ 1,400
Defray patent costs	$ 500,000
Agreement, description			The Company is required to pay as royalty, 1% of the annual net sales of the licensed product(s) used, leased, or sold by or for licensee or its sub-licensees. If the Company sublicenses the technology, it is also required to pay an amount equal to 10% of the net sales of the sub-licensees. In addition, on December 23, 2016, as required by the license agreement, the Company paid an initial fee of $250,000 to JMHMD, and issued to it 10,000 Series C Units, valued at $250,000. The $0.5 million of value provided to JMHMD for the license agreement, along with professional fees of approximately $27,000, were recorded as an intangible asset that is amortized over the life of the license agreement which was defined as 20 years. Further, expenses related to the furtherance of the CD271+ technology is being capitalized and amortized as incurred over 20 years. There were no license fees due for the years ended December 31, 2022 and 2021 pertaining to this agreement.			“Approval” refers to Product approval, licensure, or other marketing authorization by the U.S. Food and Drug Administration, or any successor agency. The amendments also provided for the Company’s license of additional technology, to the extent not previously included in the UM License, and granted the Company an exclusive option to obtain an exclusive license for (a) the HLHS IND with ckit+ cells; and (b) UMP-438 titled “Method of Determining Responsiveness to Cell Therapy in Dilated Cardiomyopathy.”
Master Services Agreements [Member]
Commitments and Contingencies (Details) [Line Items]
Expenditure amount						$ 2,900
Payments totaling						1,000
Consulting Services Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Company expense					$ 265,000
Accrued balance						$ 22,000			$ 164,000
Series C Units [Member]
Commitments and Contingencies (Details) [Line Items]
Shares issued (in Shares)								410		820	1,901
Class A Common Stock [Member]
Commitments and Contingencies (Details) [Line Items]
Converted shares (in Shares)						16,755

Employee Benefits Plan (Details

Employee Benefits Plan (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Employee Benefits Plan [Abstract]
Company contribution	$ 88,000	$ 66,000

Income Taxes (Details)

Income Taxes (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Income Taxes (Details) [Line Items]
Federal taxes	$ 23
State taxes	$ 22.8
Ownership change more than percentage	50%
Ownership [Member]
Income Taxes (Details) [Line Items]
Ownership percentage	50%

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of deferred tax assets or liabilities - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating loss carry forwards	$ 6,103,000	$ 2,250,000
ASC842 Lease liability	690,000	3,142,000
Equity based compensation	1,993,000	1,641,000
Fixed assets	435,000
Intangible assets	45,000
Capitalized research & development expenses	1,753,000
Changes in accrual and other expenses	911,000	240,000
Total deferred tax assets	11,930,000	7,273,000
Valuation allowance	(11,524,000)	(5,665,000)
Deferred tax assets, net of valuation allowance	406,000	1,608,000
Deferred tax liabilities:
ASC842 Right-of-use asset	(406,000)	(1,813,000)
Changes in other assets		227,000
Depreciation and amortization		(22,000)
Total deferred tax liabilities	(406,000)	(1,608,000)
Deferred tax assets and liabilities, net of valuation allowance

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of federal and state statutory tax rates and the provision for income tax benefit	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of federal and state statutory tax rates and the provision for income tax benefit [Abstract]
Federal tax at statutory rate	21%	21%
State tax benefits, net of federal benefit	6.90%	3.70%
Other	0.80%	3%
Change in valuation allowance	(28.70%)	(27.70%)
Income tax benefit

Loss Per Share (Details) - Sche

Loss Per Share (Details) - Schedule of calculation of diluted net loss per share - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of calculation of diluted net loss per share [Abstract]
RSUs	$ 330	$ 197
Stock options	470	304
Warrants	1,271	1,271
Total	$ 2,071	$ 1,772

Reclassification of Prior Yea_2

Reclassification of Prior Year Presentation (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($)
Summary of Significant Accounting Policies [Abstract]
General and administrative expenses	$ 1

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)							1 Months Ended	3 Months Ended
	Jan. 03, 2023	Oct. 03, 2022	Jul. 01, 2022	Apr. 01, 2022	Jan. 03, 2022	Oct. 01, 2021	Feb. 22, 2023	Dec. 31, 2023	Sep. 01, 2023	Jul. 01, 2023	Apr. 01, 2023
Subsequent Events (Details) [Line Items]
Vested shares		18,001	18,002	26,360	29,614	33,022
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Vested shares							50,000
Closing price per share (in Dollars per share)	$ 3.37
Company paid employer taxes (in Dollars)	$ 17,000
Annual salary (in Dollars)							$ 530,000
Annual cash bonus percentage							70%
Based on achievement percentage							80%
Discretionary percentage							20%
Performance share units							125,000
Subsequent Event [Member] | Maximum [Member]
Subsequent Events (Details) [Line Items]
Tax liability (in Dollars)	15,000
Subsequent Event [Member] | Minimum [Member]
Subsequent Events (Details) [Line Items]
Tax liability (in Dollars)	$ 2,000
Subsequent Event [Member] | Class A Common Stock [Member]
Subsequent Events (Details) [Line Items]
Tax liability shares	4,431
Forecast [Member]
Subsequent Events (Details) [Line Items]
Restricted stock unit								50,000	50,000	50,000	50,000
Restricted Stock Units (RSUs) [Member] | Subsequent Event [Member] | Maximum [Member]
Subsequent Events (Details) [Line Items]
Vested shares	20,161
Restricted Stock Units (RSUs) [Member] | Subsequent Event [Member] | Minimum [Member]
Subsequent Events (Details) [Line Items]
Vested shares	18,005